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Introduction 
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Natural products are small organic molecules produced by living organisms. They are 
usually called secondary metabolites because these molecules are not essential for the survival 
of organisms. Secondary metabolites are produced from key intermediates of the primary 
metabolism and relatively limited in occurrence and are often unique to particular groups of 
organisms or even species [1]. Secondary metabolites normally represent a chemically 
extremely diverse group of organic molecules and include products as a consequence of 
nutrient limitation, compounds for defense, regulatory molecules, or signaling molecules [1]. 
Secondary metabolites can be classified on the basis of the primary metabolic pathway from 
which they are derived or in terms of their structural similarity [1]. In contrast to secondary 
metabolites, primary metabolites are essential for life, and include proteins, carbohydrates, 
lipids, nucleic acids, and their precursors and these molecules are produced by metabolic 
pathways common to most of organisms and include all of the modes of synthesis, 
interconversion, or degradation involved with the production of primary metabolites [1,2]. 
Historically, higher plants are considered as the most important source of drugs and 
medicinal plants are well documented throughout human history. In the history of natural 
product drug discovery, synthesis of acetylsalicylic acid (aspirin), an anti-inflammatory agent 
derived from the salicin, the natural product originally isolated from the bark of willow trees 
is one of the most noted examples [3] (Figure 1-1). Investigation of Papver somniferous (opium 
poppy) resulted in the isolation of morphine including several alkaloids, commercially 
available as analgesic agent, first reported in 1800s [4]. The bark of Cinchona succirubra had 
been used for the centuries for the treatment of fever and malaria [5], and the active component 
of bark of Cinchona succirubra was identified as quinine, and commonly used as anti-malaria 
drug and approved by the Food and Drug Administration (FDA) in 2004 [2]. Pilocarpine, L-
histidine-derived alkaloid isolated from Pilocarpus jaborandi, which has been used as a drug 
for the treatment of glaucoma for over centuries and an oral formulation of pilocarpine was 
approved by the FDA in 1998 for the treatment of dry mouth (xerostomia) [2]. 
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Figure 1-1. Examples of plant-derived drugs. 
Traditionally, microbial natural product drug discovery program includes the isolation of 
targeted microorganisms, fermentation of individual isolated strains, and extraction of 
fermentation broth with desired organic solvent and if the extract showed any activity in 
bioassays, then each compound from extract was isolated and the structure was elucidated, and 
biological activity of pure compound was evaluated [6]. The modern era of antibiotic 
chemotherapy was started with introduction of penicillin in 1940s in clinical trials for the 
treatment of bacterial infections. Penicillin was first discovered on September 3, 1928 with the 
somewhat serendipitous event by Sir Alexander Fleming as a secondary metabolite derived 
from fungus Penicillum notatum [7]. After the first clinical use of penicillin in 1940s, there was 
a worldwide search for new antibiotics from microorganisms and bioactive natural products 
began [2]. Another important milestone in the history of antibiotics was the discovery of 
streptomycin from Streptomyces griseus, the first aminoglycoside antibiotic, in 1943 by 
Selman Waksman [8]. Chloramphenicol is a broad-spectrum antibiotic originally isolated from 
Streptomyces venezuelae in 1947. It was the first antibiotic synthesized by chemical means 
soon afterwards its structure was determined [9]. The first tetracycline antibiotic discovered, 
aureomycin, was isolated in 1948 from soil derived Streptomyces aureofaciens [10]. 
Erythromycin is the first macrolide antibiotic introduced into clinincal practice since 1952 was 
isolated from Streptomyces erythraeus [11]. Vancomycin is a glycopeptide antibiotic used for 
the treatment of methicillin-resistant Staphylococcus aureus. It was originally discovered from 
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Streptomyces orientalis isolated from soil sample in 1956 [12]. Doxorubicin is one of 
anthracycline family of antibiotic originally isolated from Streptomyces peucetius from soil of 
sourthern Italy in 1957, is a potent chemotherapeutic agent to treat various types of liquid and 
solid tumors [13,14]. Avermectins are series of antihelmentic drugs originally discovered from 
fermentation broth of Streptomyces avermitilis isolated from a soil sample in Japan [15]. Most 
of antibiotic classes in use today were identified in the 1940-1960s, a period referred to as the 
antibiotic golden age [16] (Figure 1-2). 
 
Figure 1-2. Examples of representative drugs discovered from microorganisms. 
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Recently, the rate of discovery of novel bioactive compounds from well-established 
traditional terrestrial sources have fallen dramatically [17], which in some extent preclude 
researchers to use common source for the quest of new bioactive compounds and lead 
researchers to explore new, unexplored, unusual and extreme habitat such as the marine 
environment, for potentially new biosynthetic diversity [18]. Principally, unexplored organisms 
represent the best way of discovery new metabolites because of divergence of biosynthetic 
pathways [19]. Two points should be considered when researchers seeking for new bioactive 
compounds such as (i) geographically untapped sources, and (ii) overlooked group of 
organisms [20]. 
1-1 Marine Natural Products as a Source of Pharmaceuticals 
Natural products are organic molecules derived from living organisms such as plant, 
animals and microbes. They have been exploited by people for various purposes such as 
fragrances, food, medicine, pigments, and insecticides [21]. They often traditionally called 
secondary metabolites and it is restricted to small molecules less than 3,000 Daltons [22]. These 
molecules are not essential to the normal growth, development or reproduction of an organism 
[23], but they are important for survival, defending (e.g. against predators or prey organisms) 
or attracting (e.g. odorant fragrances of plants attracting insects attract animals for pollination 
and seed dispersal) other organisms [22]. These compounds are mostly genetically encoded 
and produced by secondary metabolic pathways [24,25]. About 50-70% of all therapeutical 
agents in clinical use today are natural products insipired by such small molecules [26]. 
Oceans cover more than 70% of the Earth’s surface and host a vast species diversity, and 
there are still immense untapped resources available for the drug discovery [27]. Some marine 
ecosystems such as coral reefs are thought to surpass even tropical rain forest in terms of 
species diversity [28]. This species diversity provided by the marine environment can be 
anticipated to translate into structural diversity at the level of secondary metabolite production 
[29,30]. Marine organisms represnt the most recent source of novel bioactive natural products 
as compared terresterial plants and non-marine microorganisms [31]. Marine natural products 
show a great varitey of biological activities, which play a pivotal role in the discovery of drugs 
for the treatment of human diseases [32,33]. 
Extreme enviroments are unsual, yet promising sources of new bioactive molecules [34]. 
Organisms residing unexplored harsh environment such as marine enviroments featured by 
high salinity, low oxygen concentration, extreme temperature (low and high), high pressure 
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and limited light availabity favored the production of therapeutically invaluable molecules. To 
live under such harsh conditions, organisms must physioloigally and biologically adapted for 
survival. Such adaptations usually involve modification of metabolic pathways of organisms 
resulting in production of a great variety of molecules bearing unique structures in terms of 
structural diversity and functional features [31]. 
Marine invertebrates, in particular, have proven to be major sources of marine natural 
products (MNPs) in clinical trials. Sponges, corals, tunicates, and molluscs are the major source 
of marine natural produts retrieved from invertebrates. It was not evident that the organism 
itself produced those natural products or symbiotic or assoictead microbes did. About 28,500 
MNPs had been identified by the end of 2016 with cytotoxic and anticancer properties [31]. 
The great majority of antibiotics currently used have been obtained from terrestrial sources, 
accounting for more than 75% of all currently used antibiotics, however antibiotics from 
marine sources have not yet been developed into any clinical trial phases. So most of research 
is devoted to the devolpment in anti-cancer drugs. 
When we trace the history of marine natural products with a clear impact on the 
development of drugs for human use, we should not forget two arabino-nucleosides 
spongothymidine and spongouridine. At first they were isolated in the early 1950s from the 
extract of sponge Tethya crypta (currently Tectitethya crypta) [35] (Figure 1-3). Two 
nucleosides, the anticancer cytarabine (ara-C) and antiviral vidarabine (ara-A), are derivatives 
of sponge dervived arabino-nucleosides were the first FDA approved marine drugs in 1969 and 
1976, respectively [31]. Untill now, nine marine-derived compounds are the FDA 
pharmaceutical drugs, and six compounds are undergoing phase III clinical trials. Fourteen 
other compounds are in phase II clinical trials, and 10 compounds are in phase I and several 
drugs in preclinical trails. Targets of these drugs include a wide range of diseases such as cancer, 
viral, Alzheimer's, chronic pain, and hypertriglyceridemia [36] (Table 1-1). 
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Figure 1-3. Structures of arabino-nucleosides. 
Marizomib (NPI-0052; salinosporamide A), a proteasome inhibitor discovered from a 
marine bacteria Salinospora tropica and Salinispora arenicola. It is undergoing phase I clinical 
trail for the treatment of solid tumors and refractory lymphoma [37]. Bryostatin, macrocyclic 
polyketide, was first isolated from the bryozoan Bugula neritina in 1968 and characterized 
chemically in 1982 and the main pharmacological mechanism of action is modulation of 
protein kinase C (PKC) activity. Bryostatin is currently in phase I clinical trial for the 
Alzheimer’s disease [38]. Plinabulin is a synthetic analogue of halimide, originally isolated 
from Aspergillus sp. Plinabulin is now undergoing phase III clinical trail against solid tumors 
and lymphomas [39]. Plocabulin, new polyketide isolated from the Madagascan sponge 
Lithoplocamia lithistoides [40]. Plocabulin currently in phase II trial in patients with advanced 
malignancies. Omega-3 acids are essential, because human do not synthesize them and three 
main types of omega-3 fatty acids are alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), 
and docosahexaenoic (DHA). EPA and DHA are found in all fish and are effective strategy for 
reducing hypertriglyceride levels in patients with hypertriglyceridemia [41]. Monomethyl 
auristatin E (MMAE) is a synthetic analog of dolastatin 10, a cytotoxic compound originally 
isolated from the the sea hare Dolabella auricularia. MMAE, as a highly potent microtubule 
inhibitor, and demonstrated wide spectrum of anticancer activity against a multitude of 
lymphomas, leukemia, and solid tumors [42] (Figure 1-4). 
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Table 1-1. Pipeline of marine pharmaceuticals until 2019 (according to 
https://www.midwestern.edu/departments/marinepharmacology/clinical-pipeline.xml, 
accessed on 27 October 2019) [36]. 
٭Antibody Drug Conjugate (Monomethylauristatin E) 
Compounds Chemical class Source organism Therapeutical use Status in 2019 
Cytarabine Nucleoside  Sponge Cancer FDA-approved 
Vidarabine Nucleoside Sponge  Antiviral FDA-approved 
Ziconotide Peptide Cone snail Chronic pain  FDA-approved 
Omega-3-acid ethyl esters Omega-3-fatty acid  Fish Hypertriglyceridemia FDA-approved 
Eribulin mesylate Macrolide Sponge Cancer FDA-approved 
Brentuximab vedotin ADC (MMAE)٭ Mollusc Cancer FDA-approved 
Trabectedin Alkaloid Tunicate Cancer  FDA-approved 
Plitidepsin Depsipetide Tunicate Cancer FDA-approved 
Polatuzuman ventodin  ADC (MMAE) Mollusc Cancer FDA-approved 
Plinabulin Diketopiperazine Fungus Cancer Phase III 
Tetrodotoxin Guanidinium alkaloid Puffer fish  Chronic pain Phase III 
Lurbinectedin Alkaloide Tunicate  Cancer Phase III 
Marizomib Beta-lactone-γ-
lactam 
Bacterium Cancer Phase III 
Enfortumab ADC (MMAE) Mollusc Cancer Phase III 
Plocabulin Polyketide Sponge Cancer Phase II 
Tisotumab Vedotin ADC (MMAE) Mollusc Cancer  Phase II 
Bryostatin Macrolide lactone Bryozoan Alzheimer's  Phase I 
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Figure 1-4. Examples of marine natural products in clinical trials. 
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Chemoinformatics insight into the difference between MNPs and terrestrial natural 
products (TNPs) revealed that MNPs have lower solubility and are often larger than TNPs. 
MNPs possess longer chains and larger rings, usually the 8- to 10- membered rings containing 
ester bonds, which facilitate marine organisms to adapt to the water habitat, while the scaffolds 
of TNPs often have more stable ring systems and bond types. MNPs contain more halogens, 
because halogens are prevalent in seawater, and nitrogen and less oxygen atom compare to 
TNPs, which is indicative of MNPs may be synthesized by more diverse biosynthetic pathways 
than TNPs [43]. 
The main drawback of MNPs for drug discovery is the supply problem because active 
MNPs obtained from natural sources are in very minute amounts [31]. Total chemical synthesis 
or semi synthesis is the most useful technique to solve this problem [31]. Biotechnological 
techniques such as large scale fermentation of producing microorganisms, aquaculture of 
invertebrates, change in nutrient regimes of media, change in physical parameter of cultivation 
media, co-cultivation such as prokaryote-prokaryote co-cultivation, prokaryote-eukaryote co-
cultivaton, addition of chemical elicitors, addition of adsorptive polymeric resin in 
fermentation media and high throughput methods to streamline cultivation could be helpful for 
mass production of natural products from marine organisms [31,44]. 
1-2 Natural Products from Corals 
Corals are large, diverse group of sessile marine invertebrates belonging to the phylum 
Cnidaria include over 7,500 species [45]. Corals are the one of the most prolific sources of 
marine natural products ranking next to sponges in marine invertebrates [46]. Corals are 
basically classified into stony and soft corals. Stony corals are reef-building scleractinian corals 
and contain skeleton made of calcium carbonate and soft corals lacking calcium carbonate 
skeleton and includes a range of species, like gorgonians, sea fans, sea whips, sea pens, sea 
feathers, and blue corals. Soft corals are not responsible for reef building but may live in them 
[47-50]. To date, there have been more than 5,800 compounds reported from corals all over the 
world, attributing almost 20% of the total marine natural products. These natural products are 
mostly representative as terpenoids and steroids [45]. 
1-2-1 Natural Products from Soft Corals 
Soft corals are promising potential source of marine natural products among marine 
organisms and received significant attention. Many bioactive compounds with diverse 
structures include diterpenes, sesquiterpenes, steroids and other chemical types have been 
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isolated from soft corals. The natural products retrieved from soft corals showed wealth of 
biological activities such as antimicrobial, antiviral, anticancer, antifouling and anti-
inflammatory (Figure 1-5). Some of those compounds isolated from soft corals have provided 
a great opportunity for the development of new pharmaceuticals and antifoulants [51-59]. 
 
Figure 1-5. Chemical structures of new bioactive compounds from soft corals. 
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1-2-2 Natural Products from Stony Corals 
Stony corals (or Scleractinian, hard coral, hexacoral, reef-building coral, hermatypic 
coral) has been rarely investigated for their ability to produce bioactive natural products, 
different from soft corals. The reason behind it is that researchers consider stony corals would 
hardly produce secondary metabolites as they consist mostly calcareous skeleton which is 
responsible for defensive role and thus the organic material is relatively few to the body weight. 
However, in soft corals secondary metabolites are produced to protect soft corals from 
predators because of lacking physical means of defense. New natural products obtained from 
stony corals usually belong to chemical classes such as alkaloids, sesterterpenes, 
anthraquinoids, phenols, macrolides, and acetylenic compounds. Many of them showed 
intriguing biological activities, such as antiviral, antibacterial, and cytotoxic activity (Figure 1-
6).  
Tubastrine, a new guanidinostyrene derivative was isolated from the acetone extract of 
stony cooral Tubastrea aurea. Tubastrine exhibited antiviral activity [60]. Brine shrimp 
lethality assay guided fractionation of stony coral Montipora sp. led to the discovery of N-alkyl 
pyridinium alkaloid, montipyridine [61]. This compound showed cytotoxic activity against 
panel of human cancer cell lines, A549 (human lung cancer), SK-OV-3 (human ovarian cancer), 
SK-MEL-2 (human skin cancer), XF498 (human CNS cancer), and HCT15 (human colon 
cancer) with ED50 values higer than 30 µg/mL. Aplysinopsin derivative was isolated from 
ethanol extract of stony coral Tubastrea aurea by solvent/solvent fractionation and silica gel 
column chromatography. This inhibits the first cleavage of fertilized sea urchin eggs at 2.5 
µg/ml [62]. Ethanol extract of air dried sample of stony coral Tubastraea micrantha followed 
by defatting with hexane and extracted with CHCl3 and LH-20 purification and finally purified 
by RP-8 column led to the discovery of alkaloid designated tubastraine [63]. Two new 
macrolide derivatives, mycalolides D and E, were isolated from organic extract of stony coral 
Tubastraea faulkneri [64]. Mycalodie D showed modest cytotoxicity against NCI-60 cancer 
cell line panel with LC50 value of 0.6 µM. Two new polyacetylene carboxylic acids, montiporic 
acids A and B, were isolated from the stony coral Montipora digitate [65]. Montiporic acid A 
showed antimicrobial activity against Escherichia coli but, also cytotoxicity against P-388 
murine leukemia cells with IC50 value of 5 µg/mL. Six new acetylenic compounds including 
montiporyne A with cytotoxic activities against human solid tumor cell lines (SKOV-3, SK-
MEL-2, XF498, and HCT15) were isolated from the stony coral Montipora sp [66]. 
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Montiporyne A exhibited cytotoxicity against human cell lines SK-MEL-2 with ED50 value of 
1.4 µg/mL. 
 
Figure 1-6. Chemical structures of natural products from stony corals. 
Over the last decade, number of publications and number of new compounds from corals 
has been slightly decreased, whereas number of publications of new compounds from coral-
associated microorganisms is slightly increasing [67]. Although corals and other marine 
invertebrates are rich source of bioactive natural products with a wide range of bioactivities, 
their pharmaceutical potential to drug discovery is often hindered by a supply problem. These 
marine invertebrates produce bioactive natural products in very minute amounts and it is need 
to collect a large amount of animal samples for extraction and ultimately drug discovery. Thus, 
the exploitation of bioactive natural products from corals for drug developments is still 
restricted by a supply problem and the need of sustainable conservation of coral reefs. So it is 
rational to use host-associated microorganisms for the bioactive natural products because 
associated microorganisms also produce a wide range of bioactive compounds. 
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1-3 Natural Products from Coral-Associated Microorganisms 
1-3-1 Microbial Community in Corals 
Corals are colonized by bacteria and other microorganisms, and the relation between 
corals and their colonized microbes vary from commensal to mutualistic or pathogenic or 
having no effect [68,69]. Corals harbor diverse and abundant microbial community, mainly 
consisting of eukaryota, bacteria, and archaea, as well as numerous viruses [70]. Corals live in 
symbiosis with unicellular dinoflagellate algae, commonly called zooxanthellae. In this 
association, dinoflagellate algae of genus Symbiodinium (zooxanthellae) lives within the 
gastrodermal cells of the coral host [70]. In this relationship, both corals and Symbiodinium are 
benefited. Corals provide protection of environment and compounds needed for the 
photosynthesis, whereas Symbiodinium furnish corals with glucose, glycerol and amino acids, 
which are products of photosynthesis [72]. Symbiodinium cells also provide pigmentation to 
corals [73] (Figure 1-7). Microorganisms are usually found in the coral surface mucus, coral 
tissue, and calcium carbonate skeleton and some particularly associated with Symbiodinium 
and each of which harbor distinct bacterial population [74]. It is assumed that coral-associated 
microorganisms are playing critical role in the chemical defense of their hosts by production 
of secondary metabolites [75]. In addition, microorganisms-associated with corals contribute 
to carbon cycling, sulfur cycling, nitrogen fixation, and phosphorous fixation [76]. However, 
some bacteria associated with corals also have negative effect on corals, including pathogenic 
bacteria such as Vibrio species, Aspergillus sydowii, Serratia marcescens, Thalassomonas 
loyan and Aurantimonas coralicida. These are the major group of bacteria responsible for the 
diseases of corals [77]. Study on bacteria associated with corals has been mainly focused on 
stony corals. Studies on the genetic diversity of bacteria associated with corals have disclosed 
extreme species richeness and abundance [78,79]. Diverse groups of bacteria are found from 
the different parts of corals [80,81]. Proteobacteria are the most abundant class of bacteria 
associated with corals [82].  
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Figure 1-7. Symbiodinium cells in the host tissues [73]. a) Stony coral with brown coloration 
due to the presence of Symbiodinium, b) Symbiodinium cells in the gastrovascular cavity of 
larva (under a microscope) of the stony coral Mussismilia hispida. 
Some metabolites isolated from invertebrate-associated microbes are closely identical to 
compounds isolated from their hosts and sometimes associated-microbes are considered as the 
true producers of some marine bioactive compounds. For a long time, natural products of 
microbes associated with corals are largely neglected. Recently, secondary metabolites of 
associated microbes are attracting attention of researchers, mainly focused on associated fungi. 
Marine invertebrates (e.g., corals, sponges, tunicates) contain secondary metabolites in 
minute quantities, so it is inevitable to consume large amount of such organisms to get adequate 
amount of compounds for detail chemical and biological study and ultimately drug 
development. The concentrations of many highly active compounds in marine invertebrates are 
very low accounting for less than 10-6 % of their wet weight. To get approximately 1 g of 
ecteinascidin-743 (ET-743), an anticancer agent isolated from tunicate, about one metric ton 
of wet weight of tunicate Ecteinascidia turbinate must be used for extraction [83] (Figure 1-8). 
Therefore, exploration of new bioactive compounds for drug developments has been gradually 
shifted from hosts to their associated microbes. Here, bioactive new compounds from coral-
associated microorganisms are categorized into two points. 
  
a b 
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Figure 1-8. Chemical structure of ecteinascidin-743 (ET-743). 
1-3-2 Bioactive Compounds from Soft Coral-Associated Microorganisms 
A handful of bioactive compounds were discovered from soft coral-associated bacteria, 
actinomycetes and fungi with a wide range of bioactivity like antimicrobial, antifungal, 
anticancer, antibiofilm or anti-inflammatory activity. Comparing to bacteria and actinomycetes, 
substantial amount of new natural products were isolated from soft coral-associated fungi, 
mostly belonging to genus Aspergillus followed by Penicillium. 
Pseudoalteromones A and B were isolated from Pseudoalteromonas collected from the 
cultured octocoral Lobophytum crassum [84,85]. Pseudoalteromone A, a novel ubiquinone 
derivative displayed cytotoxicity toward the human acute lymphoblastic leukemia cells 
(MOLT-4) with IC50 value of 3.7 µg/mL. Pseudoalteromone B showed moderate inhibitory 
effect on the release of elastase by human neutrophils. A new 24-membered ring lactone, 
macrolactin V, was isolated from culture broth of Bacillus amyloliquefaciens collected from 
the gorgonian coral Junceella juncea [86]. Macrolactin V exerted strong antibacterial activity 
against E. coli, Bacillus subtilis, and S. aureus, with MIC value of 0.1 µg/mL. Seven novel 
maleimide derivatives, aqabamycins A-G, were isolated from culture broth of Vibrio obtained 
from soft coral Sinularia polydactyla [87]. Aqabamycins A-G showed antimicrobial activity 
against Micrococcus luteus, Bacillus subtilis, Proteus vulgaris, and Escherichia coli and the 
fungus Nematospora coryli (Figure 1-9). 
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Figure 1-9. Chemical structures of bioactive natural compounds from bacteria associated 
with soft corals. 
Five new spirocyclic polyketides, pteridic acids C-G, were isolated from Streptomyces sp. 
collected from gorgonian coral Melitodes squamata [88]. Pteridic acids C, D and E showed 
weak antibacterial activity against Bacillus subtilis with inhibition zones of 8, 7 and 7 mm, 
respectively, at the equal concentration of 50 μg per disc. Chemical investigation of culture 
broth of Streptomyces sp. isolated from gorgonian coral Melitodes squamata led to the 
discovery of five novel polyhydroxy polyketides nahuoic acids B-E [89]. These compounds 
showed weak antibiofilm activity against Shewanella onedensis MR-1 biofilm. Unidentified 
soft coral-associated Streptomyces sp. produces two chlorinated polyketides, strepchloritides 
A and B that possess cytotoxicity against breast cancer (MCF-7) cells with IC50 values of 9.9 
and 20.2 µM, respectively [90]. Chemical analysis of Streptomyces sp. collected from the 
surface of the gorgonian octocoral Pacifigorgia sp. led to the obtainment of two octatomic ring 
lactones, octalactins A and B [90]. Octalactin A exhibited strong cytotoxic activity toward 
human melanoma B-16-F10 and colon carcinoma HCT-116 cell lines with IC50 values of 7.2 x 
10-3 and 0.5 µM, respectively (Figure 1-10). 
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Figure 1-10. Chemical structures of bioactive compounds isolated from actinomycetes 
associated with soft corals. 
Chemical investigation of culture broth of Aspergillus sp. obtained from a gorgonian coral 
Dichotella gemmacea led to the discovery of two new benzylazaphilone derivatives with an 
unprecedented carbon skeleton, aspergilone A and its symmetrical dimer with a unique 
methylene bridge, aspergilone B [92]. Aspergilone A displayed cytotoxicity toward HL-60 
human promyelocytic leukemia, MCF-7 human breast adenocarcinoma and A-549 human lung 
carcinoma cell lines with IC50 values of 3.2, 25, and 37 µg/mL, respectively. Aspergilone A 
also showed potential antifouling activity against the larval settlement of barnacle Balanus 
amphitrite at nontoxic concentration with EC50 value of 7.68 µg/mL. Three phenolic 
bisabolane-type sesquiterpenoids (+)-methyl sydowate, 7-deoxy-7,14-didehydrosydonic acid, 
and 7-deoxy-7,8-didehydrosydonic acid, were obtained from the culture broth of Aspergillus 
sp. isolated from gorgonian coral Dichotella gemmacea [93]. (+)-Methyl sydowate showed 
weak antibacterial activity against Staphylococcus aureus. Investigation of Aspergillus sydowii 
associated with the sea fan (gorgonian) coral Annella sp. led to the isolation of 15 compounds, 
including three new sesquiterpenes, aspergillusenes A and B and (+)-(7S)-7-O-methylsydonic 
acid [94]. These compounds did not show antioxidant activity in antioxidant activity in the 1,1-
diphenyl-2-picrylhydrazyl (DPPH) scavenging assay. Three cyclic tetrapeptides, 
aspergillipeptides A-C, and asteltoxin B were isolated from a fermentation broth of Aspergillus 
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sp. associated with gorgonian coral Melitodes squamata [95]. Aspergillipeptide C exhibited 
strong antifouling activity against Bugula neritina larvae settlement with EC50 value of 11 
µg/mL. Four mycotoxins aluminiumneoaspergillin, zirconiumneoaspergillin, aspergilliamide, 
and aochratoxin A n-butyl ester were isolated from the culture broth of Aspergillus sp. 
associated with gorgonian coral Melitodes squamata [96]. All these compounds displayed 
strong or medium brine shrimp toxicity. Two prenylated indole alkaloids, 17-epinotoamides Q 
and M, and two new phenyl ether derivatives, cordyols D and E were obtained from static 
culture of Aspergillus sp. isolated from gorgonian coral Dichotella gemmacea [97]. 
Anthraquinone derivative, named 8-O-methylnidurufin was isolated from culture broth of 
Aspergillus sp. associated with gorgonian coral Dichotella gemmacea [98]. 8-O-
Methylnidurufin exhibited strong antibacterial activity against Micrococcus luteus with the 
MIC value of 6.25 µM (Figure 1-11). 
 
Figure 1-11. Chemical structures of new compounds isolated from Aspergillus sp. associated 
with soft corals. 
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Three new lumazine peptides, penilumamides B-D and cyclic pentapeptide, asperpeptide 
A were isolated from the gorgonian coral-associated Aspergillus sp. [99]. Steroid derivative, 
(22E)-ergosta-4,6,8(14),22,24(28)-pentaen-3-one was obtained from the culture broth of 
Aspergillus sp. isolated from a gorgonian coral Muricella abnormalis [100]. This compound 
inhibited the larval settlement of barnacle Balanus amphitrite with EC50 value of 18.40 µg/mL. 
Phenylalanine derivative, 4’-O-methyl-asperphenamate and two cytochalasins, aspochalasin 
A1 and cytochalasin Z24 were isolated from the culture broth of Aspergillus elegans obtained 
from a soft coral Sarcophyton sp. [101]. 4’-O-Methyl-asperphenamate showed selective 
antibacterial activity against Staphylococcus epidermidis with the MIC value of 10 μM. 
Nucleoside aroyl uridine derivative was isolated from fermentation broth of Aspergillus 
versicolor collected from the gorgonian coral Dichotella gemmacea [102]. This compound 
showed antibacterial activity against Staphylococcus epidermidis with MIC value of 12.5 µM. 
Spirocyclic diketopiperazine alkaloid, spirotryprostatin F was isolated from Aspergillus 
fumigatus collected from soft coral Sinularia sp. [103]. Spirotryprostatin F in low and ultralow 
doses (10-6-10-17 M) exhibited stimulating action on the growth of sprout roots of soy (Glycine 
max) buckwheat (Fagopyrum esculentum), and corn (Zea mays). Three new 
cyclopentapeptides, versicoloritides A-C, a new orcinol tetramer, tetraorcinol A, and two new 
lactones, versicolactones A and B were isolated from the fermentation broth of Aspergillus 
versicolor associated with the coral Cladiella sp. [104]. Tetraorcinol A exhibited weak radical-
scavenging activity against the DPPH radical with an IC50 value of 67 µM. Two aromatic 
butenolides, aspernolides A and B were isolated from the fermentation broth of Aspergillus 
terreus isolated from soft coral Sinularia kavarattiensis. Aspernolide A showed mild 
cytotoxicity against cancer cell lines [105]. 3-Methoxy-4-methyl-2,4-dien-pentanoic acid, was 
isolated from EtOAc extract of Aspergillus sp. collected from soft coral Sarcophyton tortuosum 
[106]. Chemical investigation on a coral-associated fungus Aspergillus terreus, led to the 
discovery three new compounds including a prenylated tryptophan derivative, luteoride E, a 
butenolide derivative, versicolactone G, and a linear aliphatic alcohol, (3E,7E)-4,8-dimethyl-
undecane-3,7-diene-1,11-diol [107]. Versicolactone G showed potent α-glucosidase inhibitory 
activity (Figure 1-12). 
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Figure 1-12. Chemical structures of new compounds isolated from Aspergillus sp. associated 
with soft corals. 
Seven aromatic polyketides, communols A-G, were isolated from the fermentation broth 
of Penicillium commune associated with the gorgonian coral Muricella abnormalis [108]. 
Communol A showed weak antimicrobial activities against Escherichia coli and Enterobacter 
aerogenes with MIC values of 4.1 and 16.4 µM, respectively. Two polyketides, 6,8,5’,6’-
tetrahydroxy-3’-methylflavone and paecilin C were obtained from a fermentation broth of 
Penicillium sp. associated with gorgonian coral [109]. 6,8,5’,6’-Tetrahydroxy-3’-
22 
methylflavone showed significant antifouling activity against Balanus amphitrite larvae 
settlement with EC50 value of 6.7 µg/mL. Dihydrothiophene-condensed chromones, 
oxalicumones A and B and a new natural chromone, oxalicumone C were obtained from a 
fermentation broth of Penicillium oxalicum associated with gorgonian coral Muricella flexuosa 
[110]. Oxalicumones A and B showed moderate cytotoxicity against A375 and SW-620 cell 
lines. Three azaphilone derivatives, pinophilins D-F and one diphenyl ether derivative, 
hydroxypenicillide were isolated from Penicillium pinophilum associated with gorgonian coral 
[111]. Five polyketides including two benzopyranones, one isochroman and two 
anthraquinone-citrinin derivatives were isolated from the culture broth of Penicillium citrinum 
associated with gorgonian coral [112]. Penicillanthranin A showed displayed moderate 
antibacterial activity against both Staphylococcus aureus and methicillin-resistant S. aureus 
with equal MIC value of 16 µg/mL. Two 2,5-piperazinedione derivatives, janthinolides A and 
B were isolated from the fermentation broth of Penicillium janthinellum collected from soft 
coral Dendronephthya sp. [113] (Figure 1-13). 
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Figure 1-13. Chemical structures of new compounds isolated from Penicillium sp. associated 
with soft corals. 
Chlorinated benzophenone derivative, (±)-pestalachloride D was isolated from 
Pestalotiopsis sp. isolated from a soft coral Sarcophyton sp. [114]. (±)-Pestalachloride D 
exhibited moderate antibacterial activity against Escherichia coli, Vibrio anguillarum and 
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Vibrio parahaemolyticus with MIC values of 5.0, 10.0 and 20.0 μM, respectively. Chemical 
investigation of culture broth of Cladosproium sp. collected from a gorgonian coral 
Anthogorgia ochracea led to the discovery of a bicyclic lactam, cladosporilactam A with 
promising cytotoxic activity against cervical cancer HeLa cell line with an IC50 value of 0.76 
μM [115]. Five triquinane-type sesquiterpenoids, chondrosterins A-E and the known 
sesquiterpenoid hirsutanol C were isolated from fermentation broth of Chondrostereum sp. 
collected from soft coral Sarcophyton tortuosum [116]. Chondrosterin A displayed significant 
cytotoxic activities against cancer lines A549, CNE2, and LoVo with IC50 values of 2.45, 4.95, 
and 5.47 μM, respectively. Chemical investigation of Eurotium rubrum associated with soft 
coral Sarcophyton sp. led to the discovery of two new sulfur-containing benzofuran derivatives, 
eurothiocins A and B. Both compounds showed potent inhibitory effects against α-glucosidase 
activity [117]. Anthraquinone alterporriol Q and the hydroanthraquinone 
tetrahydroaltersolanol C were isolated from a static culture broth of Alternaria sp. retrieved 
from a soft coral Sarcophyton sp., showed antiviral activity against the porcine reproductive 
and respiratory syndrome virus (PRRSV) [118]. Two C12 polyketides, cladospolides E and F 
were isolated from Cladosporium sp. associated with a soft coral [119]. Cladospolide E showed 
potent lipid-lowering activity in HepG2 hepatocytes. Nigrospoxydons A-C and 
nigrosporapyrone, were obtained from Nigrospora sp. associated with a sea fan coral Annella 
sp [120]. Nigrospoxydon A displayed antibacterial activity against S. aureus and MRSA with 
MIC values of 64 and 128 µM, respectively. Four pyrone derivatives, nigrosporapyrones A-D, 
were isolated from the culture broth of Nigrospora sp. associated with sea fan coral Annella sp. 
[121]. Nigrosporapyrone A showed antibacterial activity against Staphylococcus aureus with 
MIC value of 128 µM. A cytochalasin derivative, xylarisin was isolated from Xylaria sp. 
associated with the gorgonian coral Annella sp. [122]. Xylarisin showed weak antibacterial 
activity. Hirsutane sesquiterpenoid, hirsutanol E was isolated from EtOAc extract of 
Chondrostereum sp. collected from soft coral Sarcophyton tortuosum. Hirsutanol E displayed 
potent cytotoxicity toward several cell lines [100] (Figure 1-14). 
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Figure 1-14. Chemical structures of new compounds isolated from other fungi associated with 
soft corals. 
1-3-3 Bioactive Compounds from Stony Coral-Associated Microorganisms 
Soft-coral associated microorganisms are attracting attention of researchers for 
discovering novel bioactive compounds. Meanwhile, stony coral-associated microorganisms 
are not exploited for screening of new bioactive compounds. Although stony coral-associated 
bacteria showed higher bioactivity than soft coral-associated bacteria, their secondary 
metabolites are not studied extensively [124]. This is maybe because only limited compounds 
were reported from stony corals and researchers speculate that the presence of calcium 
carbonate skeleton and very few amount of organic compounds hinders to get novel bioactive 
compounds from them. In addition, sustainable conservation of coral reefs, stony corals (reef 
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building corals) cannot be taken for the drug discovery. However, several studies revealed the 
presence of diverse and abundant microbial community in stony corals [125-130]. 
Stony coral-associated bacteria were selected for the screening of new bioactive 
compounds in this study because stony corals and its associated microorganisms are largely 
neglected for drug discovery and using new source, which has not been exploited for isolation 
of microorganism, ensure the isolation of new microbes with genome containing different 
biosynthetic pathway. To the best of our knowledge, no studies have been published with 
respect to new compounds from microorganisms residing stony corals before this work. So this 
study was conducted to estimate the ability of bacteria associated with stony corals to produce 
new bioactive compounds.  
Literature reviews divulged that coral-associated microorganisms are the source of 
structurally diverse metabolites with various bioactivities. These compounds include 
polyketones, pyrones, cyclic peptides, lactones, alkaloids and so on, and show promising 
activities such as cytotoxicity, antibacterial, antifouling, phytoregulatory, and antiviral etc., 
which suggested that coral-associated microorganisms are promising source for finding new 
compounds with diverse activities. Most of the research focused on fungi associated with soft 
corals and, but only limited research has done with bacteria associated with soft corals. Many 
cultivable associated microorganisms have not been thoroughly exploited in terms of natural 
product biosynthesis abilities. Natural products derived from coral-associated microorganisms 
are still in their infancy. 
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CHAPTER 2 
 
General Methodology 
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2-1 Collection of Stony Corals 
Stony corals were obtained from aquarium vendors in Nagasaki and Osaka, Japan. Upon 
arrival of corals in our laboratory, they were kept alive in an aquarium tank until use for the 
isolation of bacteria. 
2-2 Isolation and Identification of Coral-Associated Bacteria 
In this study, aquacultured, healthy stony corals were used for isolation of bacteria. 
Bacteria were isolated by serial dilution and spread plate technique as follows: a small fragment 
of coral was taken and washed with sterile natural seawater to remove dirty particles and 
transiently attached microorganisms, then the surface was sterilized by using 70% ethanol to 
kill transiently associated microorganisms, and then washed with sterile natural seawater to 
remove the toxic effect of ethanol. A fragment of coral (ca. 1 g) was homogenized with mortar 
and pestle with an equal volume of natural seawater (1 mL), then 10-fold serial dilution was 
made up to 10-5, and 0.1 ml of each dilution liquid was plated onto Marine Agar 2216 (Difco). 
The plates were incubated at room temperature for 2 to 5 days and after two days of incubation 
at ambient temperature, single colonies were transferred onto Marine Agar and cultures were 
further purified using the same agar until to get axenic cultures (Scheme 2-1). Pure bacterial 
cultures were preserved by cryopreservation at -85oC in 20% glycerol in Marine Broth. 
 
Scheme 2-1. Isolation of bacteria from stony corals. 
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Bacterial strains were identified by 16S rRNA gene sequencing. The 16S rRNA gene of 
strains were amplified from a single colony by PCR with GoTaq Green Master Mix (Promega) 
with two universal primers (27F and 1492R). The PCR reaction was started with denaturation 
98oC for 2 min followed by total 40 cycles that consisted of denaturation at 98oC for 10 sec, 
annealing at 55oC for 30 sec, and extension at 68oC for 10 sec. PCR products were assessed by 
1% agarose gel electrophoresis (1X TAE, 1% agarose w/v). Purification of the PCR products 
were carried out according to the protocol of the Fast Gene Gel/PCR Extraction Kit (Nippon 
Genetics Co. Ltd.). The amplified 16S rRNA gene products were sequenced by Eurofins 
Genomics K. K., Tokyo, Japan. 
2-3 Fermentation, Extraction, Isolation and Purification of Natural Products from 
Bacteria Associated with Stony Corals 
Bacterial strains were cultured on Marine Agar was inoculated into 500 mL K-1 flask 
containing 100 mL of Marine Broth (Difco) or V-22 as seed medium. The flask was placed on 
a rotary shaker (200 rpm) at 30oC for 2 days. The seed culture (3 mL) was transferred into 500 
mL K-1 flasks each containing 100 mL of A3M, A11M and A16 production medium (Table 2-
1). All fermentation media except Marine Broth were prepared in natural seawater collected in 
Toyama Bay, Toyama, Japan. In order to increase the productivity of bacterial strains, HP-20 
was added to fermentation broth, which adsorbs metabolites and minimize the toxic effects of 
produced metabolites [1]. The pH of the medium was adjusted to 7.0 before sterilization. The 
inoculated flasks were placed on a rotary shaker (200 rpm) at 30oC for 5 days. n-butanol was 
selected as a solvent for the extraction, because n-butanol has a wide solubility range from 
hydrophilic to hydrophobic compounds, but remove high molecular compounds such as 
polysaccharides and proteins in order to separate into organic and water layer [2]. After 
fermentation, 100 mL of 1-butanol was added to each flask, and the flasks were allowed to 
shake for 1 h. The mixture was centrifuged at 6000 rpm for 10 min, and the organic layer was 
separated from the aqueous layer. Purification of crude extract was carried out by mainly three 
steps. Firstly, crude extract was purified by silica gel column chromatography or 
solvent/solvent extraction, followed by ODS column chromatography and final purification 
was achieved by semi-preparative HPLC. 
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Table 2-1. Composition of seed culture and production culture media.  
Media Composition  
Marine 
Broth 
peptone 0.5%, yeast extract 0.1%, and major consitutents of inorganic salts present in 
seawater 
V22 soluble starch 1%, glucose 0.5%, NZ-case 0.3%, yeast extract 0.2%, Tryptone (Difco 
Laboratories) 0.5%, K2HPO4 0.1%, MgSO4·7H2O 0.05% and CaCO3 0.3% 
A3M glucose 0.5%, glycerol 2%, soluble starch 2%, Pharmamedia (Traders Protein) 1.5%, 
yeast extract 0.3% and Diaion HP-20 (Mitsubishi Chemical, Japan) 1% 
A11M glucose 0.2%, soluble starch 2.5%, yeast extract 0.5%, polypeptone (Wako Pure 
Chemical Industries, Ltd.) 0.5%, NZ-amine (Wako Pure Chemical Industries, Ltd.) 
0.5%, CaCO3 0.3%, and Diaion HP-20 (Mitsubishi Chemical Co.) 1% 
A16 glucose 2%, Pharmamedia (Traders Protein) 1%, CaCO3 0.5%, and Diaion HP-20 
(Mitsubishi Chemical, Japan) 1% 
 
2-4 HPLC-UV Screening of Metabolites of Bacteria Associated with Stony Corals 
Chemical screening was employed to discover new compounds from bacteria associated 
with stony corals. HPLC-UV was used for chemical screening of compounds. Two milliliter of 
1-butanol extract was put into vial and dried by vacuum centrifugation. Dried extract was 
resupeneded in 200 µL DMSO and filtered using 0.45 µm membrane filter before HPLC-DAD 
analysis. The extract metabolites were separated using reversed-phase HPLC and photodiode 
array detector (200-600 nm) was used to record their characteristic UV spectra. The conditions 
for the HPLC analysis were as follows: Varian Microsorb C18 column (4.6 x 100 mm) on an 
Agilent HP1100 system with a binary pump equipped with DAD for 200 to 600 nm. The mobile 
phase used the following stepwise gradient of acetonitrile (MeCN) and 0.1% formic acid at pH 
2.7: 15% MeCN for 0-3 min, 15-85% MeCN for 3-25 min, 85% MeCN for 25-29 min and 85-
15% MeCN for 29-32 min, with a flow-rate of 1.2 mL/min (Scheme 2-2).  
Normally peaks with similar UV absorbance with in house-UV database were not 
considered for further study. However, this was a preliminary study conducted to assess the 
biosynthetic ability of associated bacteria to produce new compounds and our in-house 
database mainly contain UV of actinomycetes and fungi and lacking UV data for bacteria. UV 
only represent the chromophore present in the molecules but not the complete structure of 
molecules. So I considered to work with UV have hit from in-house database. Peaks with 
selected UV absorbance were considered for further purification and structure determination. 
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Scheme 2-2. Screening of metabolites of bacteria isolated from stony corals. 
2-5 Structure Determination 
Structure of pure compounds were determined by high resolution-mass spectrometer (HR-
MS) and one dimensional and two dimensional NMR techniques and corroborated with optical 
rotation, UV spectrometry and IR spectrometry. Bioassays for new compounds were performed. 
2-6 Dereplication of Natural Products Using HPLC-UV 
Screening of natural products for novel bioactive compounds becomes increasingly a 
challenge. The chance of finding new bioactive compounds have become more arduous due to 
astronomical number of known compounds already reported in literatures. A major problem of 
finding new bioactive compounds from natural products is reisolation of known compounds. 
Reisolation of known compounds wastes time, money and resources, and easily distracts 
natural product chemists for more promising leads for drug discovery, and to obviate such 
reisolation and recharacterization of known compounds, dereplication process should be 
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considered before isolation of target compounds. The rapid characterization of known 
compounds, a process known as dereplication, has become strategically important for natural 
product chemists involved in screening program [3]. Nowadays, several commercial databases 
have been developed that can assist the natural products chemists by avoiding unnecessary 
structure elucidation of known compounds. Several databases are available such as CAS 
Registry [4-7], CSLS [8], ChemSpider [9], PubChem [10], Dictionary of Natural Products 
(DNP) [11], Dictionary of Marine Natural Products (DMNP) [12], AntiBase [13], MarinLit 
[14], Reaxys [15], and NAPRALERT [16].  
Several combinations of LC hyphenated techniques such as LC-UV, LC-MS, LC-MS/MS, 
LC-ELSD-MS, LC-UVSPE-NMR, LC-NMR, and LC-MS/MS-NMR have been developed 
over the last three decades to obtain structural information of natural products [17]. UV is the 
simplest and most widely used detector among HPLC. Most of natural products absorb UV 
light in the range of 200-600 nm, including all substances having one or more double bonds 
and all substances that have unshared electron. Thus, even compounds with weak 
chromophores, such as triterpene glycosides, can be efficiently detected by UV at short 
wavelengths (203 nm) [18]. The major drawback of this detector is that not all natural products 
possess UV chromophores. UV spectra are easily acquired using a HPLC-UV examination of 
a crude extract or fraction. The UV profile and the maxima (λmax) of the natural products 
provide information on the chromophores and these distinctive spectral properties can be used 
for database search. For UV spectra data including, λmax and ϵ, are available in DNP and DMNP. 
However, partial UV spectral data available database are NAPRALERT, AntiMarin and 
AntiBase [19]. The UV spectra profile, including the λmax are suggestive of a chromophore 
present in a structure, which does not necessarily give the structure of the entire molecule. 
However, it offers clues for the potential substructures that can be searched for during 
dereplication process [19]. The UV spectrum is more informative other than just the λmax data. 
Matching spectra is a superior and more effective approach of UV spectra in the dereplication 
approach for natural products [19]. Such approaches are carried out by matching UV spectra 
with in-house UV spectra database [20]. Most of HPLC have the essential software for the 
capturing and comparing acquired UV spectral data. However, UV spectral data acquired from 
other HPLC cannot be compared [19]. Unfortunately, there is no UV spectral database 
available which contain other information required for the dereplication process [19]. UV data 
with mass data is a powerful and efficient tool for dereplication. 
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Fixed wavelength, multiple wavelength, and diode array detector (DAD) are the three 
main types of UV detectors which are currently available. The fixed wavelength detector has a 
higher instrinsic sensitivity and low cost because the light emitted at specific wavelengths with 
given lamp. The multiple wavelength detector is more versatile, but lower sensitivity compared 
to the fixed wavelength detector. The diode array detector (DAD) also known as photodiode 
array and provides several advantages such as peak measurement at all wavelengths, 
determination of the correct wavelengths in one run, detection of multiple wavelengths, peak 
purity analysis, scan spectrum very quickly and so on.  
In this study, HPLC-UV screening of natural products from bacteria associated with stony 
corals was used. Having some severe drawbacks, UV is still widely used in natural products 
screening because of easy to use, cheap, and adapted to a relatively large numbers of natural 
products with detection at low wavelengths. In addition, UV spectrum is only indicative of a 
chromophore present in a molecule, but not the entire structure. So there is still a chance of 
getting new molecules even after matching UV spectra profile with an in-house database if we 
are using unexplored sources or organisms from different taxonomic group for screening 
(Figure 2-1). 
 
Figure 2-1. Characteristic UV profile of a 1,2,3-trisubstituted aromatic system. 
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CHAPTER 3 
 
Labrenzbactin from a Coral-Associated 
Bacterium Labrenzia sp. C1-1 
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3-1 Background 
This study was conducted to assess the biosynthetic ability of coral-associated bacteria to 
produce new bioactive metabolites. Corals are marine invertebrates and represent one of the 
most exploited marine invertebrate for natural product discovery after sponges [1]. A wealth 
of new bioactive compounds was reported from soft corals. However, only handful of 
compounds were reported from stony corals. The reason behind it may be that researchers 
thought that stony coral rarely produces bioactive metabolites as a chemical defense as its outer 
skeleton made of calcium carbonate [2]. Recently, the rate of finding new compounds from 
common terrestrial conventional sources decrease whereas the chance of finding already know 
compounds is dramatically increases. Because there is myriad of new compounds already 
reported from common sources. So it is wise to use unexplored sources or unexploited 
organisms for the natural product discovery. The reason behind it is that there is a high chance 
of finding new organisms with diverse metabolic pathway which can lead to the discovery of 
novel bioactive compounds. Stony corals and its associated bacteria are unexplored sources 
and largely neglected for natural products screening program. In this study, stony coral-
associated bacteria were used to find new bioactive compounds because there is no any 
published report on bioactive compounds from stony coal-associated bacteria and they are 
highly ignored by scientists for screening of new bioactive compounds.  
HPLC-UV screening was employed to check the secondary metabolites produced by 
coral-associated bacterial strain C1-1. The producing strain was isolated from aquacultured 
stony coral of genus Montipora sp. Three types of fermentation media were used to compare 
the metabolite production. However, this strain produced metabolites only in A3M seawater 
fermentation broth. In the solvent extract of culture broth of C1-1 in A3M showed one major 
peak with retention time 14.2 min. The UV spectrum of peak showed absorption maxima at 
208, 250 and 314 nm (Figure 3-1). This type of UV spectrum usually represents the compound 
containing dihydroxy benzene chromophore. When I searched this UV spectrum with our in-
house database, there were two hits for known compounds such as catechoserine (211, 248, 
319 nm) [3] and ulbactin F (204, 252, 317 nm) [4]. However, our in-house database only 
contains UV spectrum for compounds retrieved from mainly actinomycetes and fungi. UV 
spectrum only gave hint of the chromophore present in the molecule. However, it could not 
give full information of the structure. This was the first time I worked with coral-associated 
bacteria and producing strain is not commonly used for natural products screening in my 
laboratory. So I decided to work with this strain although similar UV spectrum was present in 
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our in-house database. I thought that there is a chance of finding new compounds if I work with 
new bacterial strains or unexploited group of organisms obtained from unexplored sources.  
 
Figure 3-1. HPLC analysis of 1-butanol extract of producing strain Labrenzia sp. C1-1. 
The producing strain C1-1 was identified as a member of genus Labrenzia on the basis of 
99.9% similarity in the 16S rRNA gene sequence (1395 nucleotides; DDBJ accession number 
LC456786) to Labrenzia aggregata IAM 12614T (accession number AAUW01000037). The 
genus Labrenzia falls within the class Alphaproteobacteria and encompasses Gram-negative, 
motile, strictly aerobic, and rod-shaped bacteria. The Labrenzia strains require a sea salt-based 
medium for growth and they are therefore marine obligate bacteria (Figure 3-2). Labrenzia are 
usually isolated from marine habitats, in many reported cases, in association with marine 
invertebrates such as corals [5-7]. Although the species of Labrenzia possess biosynthetic 
genes for the production of polyketide, non-ribosomal peptide, and terpenoid, very little is 
known about their secondary metabolites [7]. To date, a polyketide-derived pederin-analogue 
and two cyclopropane-containing fatty acids have been reported from Labrenzia sp. (Figure 3-
3). Polyketide-derived new pederin-analogue was isolated from culture broth of Labrenzia sp. 
isolated from marine sediment. This compound showed strong cytotoxicity toward the panel 
of cell lines [8]. Similarly, chemical investigation of fermentation broth of marine sediment- 
derived Labrenzia sp. led to the discovery of two cyclopropane-containing medium-chain fatty 
acids [9]. These compounds displayed strong inhibition against wide range of bacteria and 
fungi. 
In our HPLC-UV chemical screening of secondary metabolite production by coral-
associated bacteria, Labrenzia sp. C1-1 was found to produce a new catecholate-class 
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siderohpore designated labrenzbactin (1). In this chapter, the isolation, characterization, and 
bioactivity of 1 are described. 
 
Figure 3-2. Colony morphology of Labrenzia sp. C1-1 on a) Marine Agar, b) YP medium 
(yeast extract 0.1% and peptone 0.5%) in distilled water, c) YP medium in natural seawater. 
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Figure 3-3. Chemical structures of compounds from Labrenzia sp. 
3-2 Results and Discussion 
3-2-1 Fermentation and Isolation 
The producing strain C1-1 was isolated from a cultured Scleractinian (stony) coral 
Montipora sp., and identified as a member of the genus Labrenzia by 16S rRNA gene sequence 
analysis. The fermentation broth of strain C1-1 cultured in A3M seawater medium was 
extracted with 1-butanol. After evaporation, the solvent extract was fractionated by a sequence 
of chromatographies, and final purification was achieved by reversed-phase HPLC to render 
labrenzbactin (1) (Scheme 3-1). 
a b c 
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Scheme 3-1. Isolation scheme of labrenzbactin (1). 
3-2-2 Structure Determination 
Labrenzbactin (1) was obtained as a brown amorphous solid. Its molecular formula was 
assigned as C32H36N4O10 with 17 degrees of unsaturation by HR-ESI-TOFMS that gave a 
molecular ion [M+Na] + at m/z 659.2324 (calcd for C32H36N4O10Na, 659.2329) and NMR 
spectroscopic data (Table 3-1). The IR spectrum of 1 indicated the presence of OH and/or NH 
(3313 cm-1) and carbonyl (1634 cm-1) groups. Our in-house UV database indicated that the UV 
spectrum with the absorption bands at λmax 208, 250 and 314 nm was similar to those for 
catechoserine (211, 248, 319 nm) [3] or ulbactin F (204, 252, 317 nm) [4], suggestive of the 
presence of a hydroxylated benzene ring conjugated with a double bond like a carbonyl group. 
NMR spectroscopic data of 1 revealed the presence of 32 carbons attributable to four 
carbonyl-like downfield sp2 carbons, eighteen sp2 carbons (nine are proton-bearing), eight 
methylenes, one methine, and one methoxy group (Table 3-1). COSY analysis identified proton 
resonances for three sets of 1,2,3-trisubstituted benzene rings, H8/H9/H10, H9’/H10’/H11’, 
and H8”/H9”/H10” (Figure 3-4). HMBC correlations from H8 and H10 to C6 and H9 to C5 
and C7 established the 2,3-dihydroxyphenyl substructure. An oxazoline ring was deduced from 
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the HMBC correlations from H2 and H3 to C4 and chemical shift consideration for H2, H3, 
and C4. The linkage between C4 and C5 and the attachment of C1 to C2 were determined by 
the observed HMBC correlations. Another 2,3-dihydroxyphenyl moiety consisting of the 
carbons from C5” to C10” and a 2-hydroxy-3-methoxyphenyl moiety comprising C6’ to C11’ 
were also established by analyzing HMBC correlation data. The position of the methoxy group 
was confirmed by NOE detected between H12’ and H9’. COSY spectrum also provided two 
short methylene chains from H1’ to H4’ and from H1” to H3”. Mutual HMBC correlations 
between H1’ and H1” linked these carbon chains through a nitrogen atom which was in turn 
connected with the carbonyl carbon C1 by HMBC correlations from H1’ and H1” to C1. Finally, 
two aromatic parts were connected to the methylene chains via an amide bond on the basis of 
HMBC correlations from H4’ and H11’ to C5’ and from H3” and H10” to C4” to complete the 
planar structure of 1 (Figure 3-4). This structure was further validated by analyzing the NMR 
spectral data obtained in DMSO-d6 that gave higher peak resolution for 1H NMR spectrum 
(Supplementary Information). Some of the 1H and 13C NMR signals were observed as 
duplicated peaks presumably due to the tautomeric isomerization of amide bonds but all the 
signals could be assigned to its structure (Table 3-1).  
 
Figure 3-4. COSY and key HMBC correlations for labrenzbactin (1). 
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3-2-3 Absolute Configuration  
In order to determine the absolute configuration of oxazoline moiety derived from the 
serine residue in 1, advanced Marfey’s analysis was utilized [10] (Scheme 3-2). Following 
acid-catalyzed hydrolysis, 1 was derivatized using 1-fluoro-2,4-dinitrophenyl-5-L-leucinamide 
(L-FDLA) and retention time was compared with L-serine standard that was similarly 
derivatized with L-FDLA and 1-fluoro-2,4-dinitrophenly-5-D-leucinamide (D-FDLA) using 
LC-MS. The derivatized L-serine standard with L-FDLA and D-FDLA eluted at 9.5 and 10.7 
min, respectively, while the L-FDLA derivative of the acid hydrolysate of 1 eluted at 9.5 min. 
The serine residue was determined to have the L-configuration and thus the configuration of 
C2 was established to be S (Figure 3-5 and 3-6). 
 
Figure 3-5. Structure of labrenzbactin (1). 
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Figure 3-6. HPLC chromatogram of hydrolysate from labrenzbactin (1) and comparison to 
standard amino acid, derivatized with Marfey’s reagent (FDLA). 
Column: Cosmosil AR-II (Nacalai Tesque, 2×150 mm) 
Solvent: Gradient MeCN (%): 0-30 min: 25-65% in 0.1% HCO2H 
Flow rate: 0.2 mL/min 
Mass detection: negative ion mode 
Marfey’s method is a procedure for determining the absolute configurations of 
hydrolytically accessible amino acid residues present in natural products (typically but not 
exclusively peptides) [11]. This method consists four steps: (i) the natural product is subjected 
to acid hydrolysis (6 N HCl) to release amino acid residues, (ii) the hydrolysate is derivatized 
using chiral Marfey’s reagents such as D- or L-1-fluoro-2-4-dinitrophenyl-5-alanine amide (D- 
or L-FDAA) or D- or L-1-fluoro-2-4-dinitrophenyl-5-leucinamide (FDLA) under alkaline 
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condition (1 N NaHCO3), (iii) the neutralized derivatized analyte is subjected to reversed-phase 
HPLC-UV (340 nm) analysis or HPLC-MS, using generally C18 columns, and (iv) HPLC 
retention times of derivatized amino acid residues in the analyte is compared with L and D- 
amino acid standards derivatized with Marfey’s reagent.  
Based on Marfey’s method, the relationship between the L-FDLA derivative of D-amino 
acid (D-L type) and that of L-amino acid (L-L type) is diastereomeric, and this pair of 
diastereoisomers has different retention times on chromatogram so readily separated by C18 
reveresd-phase HPLC. On the contrary, the L-D and D-L type derivatives, as well as the L-L and 
D-D type derivatives, are enantiomers, and each pair of enantiomers has the same retention time 
and cannot be separated by C18 reversed-phase HPLC (Scheme 3-2). 
 
NO2
O2N
F
H
N
NH2
O
 
D- or L-FDLA (1-fluoro-2,4- dinitrophenyl-5-leucinamide) 
 
Scheme 3-2. Principle of Marfey’s method. 
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Table 3-1. 1H and 13C NMR data for labrenzbactin (1) in CDCl3-CD3OH (9:1) or in DMSO-
d6. 
 CDCl3-CD3OH (9:1)  DMSO-d6 
Position Ca H mult (J in Hz)b HMBCb,c  Ca H mult (J in Hz)b 
1 169.8, C    168.5/168.6  
2 65.4, CH 5.16 t (8.4) 1, 3, 4  64.3 5.36 t (8.5)/5.37 t (8.5) 
3 69.0, CH2 4.48 t (8.9) 1, 2, 4  69.3 4.53 t (9.0) 
  5.08 t (7.5) 1, 2, 4   4.76 t (7.3) 
4 167.4, C    166.0  
5 110.2, C    110.1  
6 147.5, C    148.1  
7 145.0, C    145.7  
8 119.1, CH 6.99 d (7.2) 6, 10  119.5 6.96 d (7.6) 
9 119.3, CH 6.75 t (7.3) 5, 7  118.8 6.74 t (8.0) 
10 119.4, CH 7.15 d (7.9) 4, 6, 8  117.87 7.07 d (7.9) 
1’ 47.6, CH2 3.62 m 1, 2’, 1”  45.1/46.8 3.32, 3.36 m/3.54, 3.63 m 
2’ 26.3, CH2 1.82d 1’, 3’  26.1 1.63, 1.72 m 
3’ 27.0, CH2 1.72 m 1’, 2’, 4’  24.5/26.2 1.51 m/1.50 m 
4’  38.9, CH2 3.52e 3’, 5’  38.5/38.6 3.36 m/3.28 m 
5’ 169.5, C    169.49/169.53  
6’ 111.5, C    114.75/114.83  
7’ 150.0, C    150.9/151.0  
8’ 148.6, C    148.4  
9’ 114.7, CH 6.87 d (7.9) 7’, 11’  115.3 7.06f 
10’ 118.7, CH 6.72 t (7.9) 6’, 8’  117.7 6.78 t (8.1) 
11’ 118.6, CH 7.20 d (7.7) 5’, 7’, 9’  118.45/118.50 7.39 d (8.6)/7.41 d (8.6) 
12’ 56.2, CH3 3.82 s 10’  55.7 3.74 s/3.75 s 
4’-NH  7.50 br.s    8.82 t (5.4)/8.86 t (5.5) 
1” 43.3, CH2 3.46e 1, 1’, 2”, 3”  43.4/44.8 3.38 m/3.53, 3.69 m 
2” 27.2, CH2 1.82d 1”, 3”  27.1/28.5 1.77 m/1.95 m 
3” 36.1, CH2 3.29 m 1”, 2”, 4”  36.7 3.26 m, 3.39 m 
4” 170.3, C    169.7/169.9  
5” 114.5, C    114.9/115.1  
6” 149.3, C    149.6/149.7  
7” 145.8, C    146.2  
8” 118.3, CH 6.95 d (7.5) 6”, 10”  118.7 6.89 d (7.8) 
9” 118.8, CH 6.71 t (7.9) 5”, 7”  117.86 6.66 t (7.9) 
10” 116.9, CH 7.10 d (7.9) 4”, 6”, 8”  117.0/117.2 7.24 d (8.0), 7.27 d (7.9) 
3”-NH  8.03 br.s 4”   8.76 t (5.4)/8.85g 
OH      9.23 br.s 
OH      11.78 br.s 
OH      12.77 br.s 
 
a Recorded at 125 MHz (reference C 77.2 for CDCl3-CD3OH; C for 39.5 for DMSO-d6). 
b Recorded at 500 MHz (reference H 7.26 for CDCl3-CD3OH; H for 2.50 for DMSO-d6). 
c HMBC correlations are from proton(s) stated to the indicated carbon. 
d-g Overlapping signals. 
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3-2-4 Bioactivity 
Biological activity of labrenzbactin (1) was evaluated by cytotoxicity and antimicrobial 
assays. Labrenzbactin showed moderate cytotoxicity against P388 murine leukemia cells at 
IC50 13 M (IC50 of a reference drug doxorubicin: 0.018 M) and no appreciable activity in 
antimicrobial assay against Bacillus subtilis ATCC6633, Staphylococcus aureus FDA209P JC-
1, Rhizobium radiobacter NBRC14554, and Escherichia coli NIHJ JC-2. However, it showed 
weak antibacterial activity against Ralstonia solanacearum SUPP1541 and Micrococcus luteus 
ATCC9341 with MIC values of 25 and 50 g/mL, respectively. 
3-3 Conclusion 
In summary, HPLC-UV chemical investigation of a marine bacterium Labrenzia sp. 
isolated from stony coral Porites sp. led to the discovery of labrenzbactin (1). This compound 
displayed weak antibacterial and cytotoxic activity. The antibacterial activity is likely due to 
the ability of 1 to bind Fe3+, inhibiting microbial proliferation via cellular iron depletion [12]. 
This is a new member of catecholate-type bacterial siderophores in which a linear triamine, 
spermidine or norspermidine, is amidated with acyl groups containing 2,3-dihydroxyphenyl 
and/or 2-hydroxyphenyl units. Several related compounds are reported: parabactin (2) from 
Paracoccus denitrificans [13]; agrobactin (3) from a plant pathogen Agrobacaterium 
tumefaciens [14]; fluvibactin (4) and vibriobactin (5) from Vibrio fluvialis and Vibrio cholerae, 
respectively [15,16] (Figure 3-7). Labrenzia spp. have the same origin with Agrobacaterium 
tumefaciens, and they were initially called the marine Agrobacterium then it was transferred to 
new group Stappia sp. then finally transferred to new genus Labrenzia. This results showed 
that Agrobacterium sp. and Labreniza sp. are closely related. Maybe Labrenzia sp. by some 
means transferred to the marine environment and adapted to live there but still carry the 
biosynthetic gene cluster for the synthesis of siderophore, which can be expressed in iron-
difficient environment for their survivial. The concentration of dissolved iron is extrememly 
low in marine environments [17]. Iron is required for the living organisms and paly important 
role in the oxygen metabolism, electron transfer, and DNA and RNA synthesis [17]. Under the 
normal physiological condition iron is present as ferric hydroxide, higly insoluble form, which 
cannot be utilized by microorganisms [18]. To get such limited iron, microorganisms produce 
siderophores and they bind Fe3+ and transport it into the cells where it is reduced to Fe2+ and 
released from siderophore and microorgansims get iron in iron-deficient environment [19] 
(Scheme 3-3). Marine organisms like Labrenzia sp. overcome the iron limitation probably by 
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producing siderophores like labrenzbactin. Labrenzia species contains biosynthetic gene 
clusters for the production of non-ribosomal peptides, polyketides and terpenoids, but only two 
bioactive compounds are reported from this genus before this study. So Labrenzia spp. are 
underexplored bacteria with potential ability to produce secondary metabolites and waiting for 
exploitation by researchers for secondary metabolites screening program. From this study, we 
can conclude that bacterial strain retrieved from unexplored sources such as a stony coral could 
be the source of new compounds and stony coral-associated bacteria have great potential in the 
discovery of bioactive molecules. 
 
Figure 3-7. Related metabolites from bacteria, parabactin (2), agrobactin (3), fluvibactin (4), 
and vibriobactin (5). 
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Scheme 3-3. Iron acquisition by catecholate-type siderophores. 
Until now, terrestrial microorganisms especially Gram-positive Actinobacteria and 
filamentous fungi, have furnished the majority of natural drugs. Proteobacteria is the major 
phylum of Gram-negative bacteria and includes many medically important pathogens such as 
Escherichia, Salmonella, Vibrio, Helicobacter, Yersinia, and many others. Although 
Proteobacteria is the most abundant phylum in marine ecosystems representing 55% of all 
bacteria [20], only limited bioactive compounds have been isolated from them [21-33] (Figure 
3-8).
 
Figure 3-8. Selected examples of bioactive metabolites from marine Proteobacteria. 
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One of the most interesting example of such molecules is didemnin B, which was 
originally isolated from tunicate Trididemnum solidum, a potent anti-tumor agent, that was 
discovered to be a product of marine free living Alphaproteobacteria of genus Tistrella sp. by 
two independent research groups from Japan and the USA [31,32]. Most of compounds 
produced by Proteobacteria are not unique to marine environments, and are also produced by 
terrestrial microorganisms. This is likely due to the horizontal gene transfer-mediated spread 
of biosynthetic gene clusters. Bacteria of phylum Proteobacteria are dominant group in marine 
environment, because they evolved diverse metabolic and biosynthetic strategies in order to 
adapt to harsh marine ecosystems, which makes them attractive and reasonable candidate group 
of marine bacteria for large scale study for new bioactive compounds [20]. Marine 
Proteobacteria remain an intriguing source of new drug leads because up to 15% of genomes 
devoted to biosynthesis of secondary metabolites [20].  
3-4 Experimental Section 
General Experimental Procedures. Optical rotation was measured using a JASCO DIP-3000 
polarimeter. The UV spectra were recorded on a Shimadzu UV-1800 spectrophotometer. The 
IR spectrum was measured on a PerkinElmer Spectrum. NMR spectra were obtained on a 
Bruker AVANCE 500 spectrometer in a mixture of CDCl3 and CD3OH (9:1) due to the low 
solubility of 1 in a single solvent or in DMSO-d6. The residual solvent signals (CDCl3: δH 7.26 
and δC 77.24; DMSO-d6: δH 2.50 and δC 39.5) were used as internal standards. HR-ESI-TOFMS 
were recorded on a Bruker micrOTOF focus mass spectrometer. 
Microorganism. Strain C1-1 was isolated from a cultured stony coral (Montipora sp.) obtained 
from an aquarium vendor in Nagasaki, Japan. The coral specimen was washed with 70% 
ethanol and then washed with sterile natural seawater. A piece of the coral (ca 1 g) was 
homogenized by mortar and pestle with equal amount of sterile natural seawater (1 mL), and 
the suspension was diluted up to 10-5 and 0.1 ml of each dilution liquid was spread on plates of 
Marine Agar 2216 (Difco). After cultivation at 23°C for 2 days, a single colony was repeatedly 
transferred onto the same agar medium to obtain the pure isolate of strain C1-1. The isolated 
strain was identified as a member of genus Labrenzia on the basis of 99.9% similarity in the 
16S rRNA gene sequence (1395 nucleotides; DDBJ accession number LC456786) to 
Labrenzia aggregata IAM 12614T (accession number AAUW01000037). 
Fermentation. Strain C1-1 cultured on Marine Agar 2216 (Difco) was inoculated into a 500 
mL K-1 flask containing 100 mL of V-22 seed medium consisting of soluble starch 1%, glucose 
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0.5%, NZ-case 0.3%, yeast extract 0.2%, Tryptone (Difco Laboratories, Sparks, MD, USA) 
0.5%, K2HPO4 0.1%, MgSO4·7H2O 0.05% and CaCO3 0.3% (pH 7.0) in natural seawater. The 
flasks were placed on a rotary shaker (200 rpm) at 30°C for 2 days. The seed culture (3 mL) 
was transferred into 500 mL K-1 flasks each containing 100 mL of A3M production medium 
consisting of glucose 0.5%, glycerol 2%, soluble starch 2%, Pharmamedia (Traders Protein, 
Memphis, TN, USA) 1.5%, yeast extract 0.3% and Diaion HP-20 (Mitsubishi Chemical, 
Kanagawa, Japan) 1% in natural seawater. The pH of the medium was adjusted to 7.0 before 
sterilization. The inoculated flasks were placed on a rotary shaker (200 rpm) at 30°C for 5 days. 
Extraction and Isolation. At the end of the fermentation period, 100 mL of 1-butanol was 
added to each flask, and the flasks were allowed to shake for 1 h. The mixture was centrifuged 
at 6000 rpm for 10 min, and the organic layer was separated from the aqueous layer. 
Evaporation of solvent gave 5.0 g of crude extract from 2.0 L of culture. The crude extract was 
subjected to silica gel column chromatography with a step gradient of CHCl3-MeOH (1:0, 20:1, 
10:1, 4:1, 2:1, 1:1, and 0:1 v/v). Fraction 3 (10:1) was concentrated to provide a dark brown oil 
(1.0 g), which was then fractionated by reversed-phase ODS column chromatography with a 
gradient of MeCN-0.1% HCO2H (2:8, 3:7, 4:6, 5:5, 6:4, 7:3, and 8:2 v/v). Fraction 4 (5:5) was 
concentrated and extracted with EtOAc. The organic layer was dried over anhydrous Na2SO4, 
filtered, and concentered to give 96 mg of semi-pure material. Final purification was achieved 
by preparative HPLC (Cosmosil π-NAP, Nacalai Tesque Inc., 10 x 250 mm, 4 mL/min, UV 
detection at 254 nm) with 40% MeCN in 0.1% HCO2H to give compound 1 (7.8 mg, tR 22.6 
min) from 24.0 mg of semi-pure compound. 
Labrenazbactin (1): light brown amorphous solid; [α]24D +6.0 (c 0.10, 9:1 CHCl3/MeOH); UV 
(MeOH) λmax (log ε) 208 (4.81), 250 (4.33), 314 (3.87); (MeOH – 0.01 M HCl (99:1)) 208 
(4.74), 256 (4.23), 313 (3.76); (MeOH – 0.01 M NaOH (99:1)) 223 (4.78), 334 (4.03) nm; IR 
νmax (ATR) 313, 1716 cm−1; For 1H and 13C NMR data, see Table 3-1; HR-ESI-TOFMS 
[M+Na] + 659.2324 (calcd for C32H36N4O10Na, 659.2329). 
Marfey’s Analysis. A portion of 1 (0.1 mg) was hydrolyzed at 105°C with 5 M HCl (100 µL) 
for overnight in sand bath, and the reaction mixture was evaporated to dryness. A 0.1 M 
NaHCO3 solution (100 µL) was added to the dried hydrolysate of 1, as well as to standards of 
L-serine (Ser). A solution of 1-fluoro-2,4-dinitrophenyl-5-L-leucinamide (L-FDLA) in acetone 
(0.05 mg in 50 µl) was added to each reaction tube and a solution of 1-fluro-2,4-dinitrophenyl-
5-D-leucinamide (D-FDLA) in acetone (0.05 mg in 50 µL) was added to L-serine reaction tube. 
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Each tube was sealed and heated at 50°C for 30 min. To quench reactions, 0.2 M HCl (50 µL) 
was added and then diluted with 50% MeCN/0.05% TFA (100 µL, 50:50). The Marfey’s 
derivatives of the hydrolysate and standards were analyzed by LC-MS using a Cosmosil 5C18-
AR-II column (Nacalai Tesque, 2×150 mm) eluted with MeCN-0.1% HCO2H at a flow rate of 
0.2 mL/min, monitoring at 340 nm in negative ion mode. The gradient elution was set as 
follows: 0-30 min (25-65% MeCN), 30-32 min (65-100% MeCN). Retention times for the 
amino acid standard were 9.5 min for L-Ser-L-FDLA and 10.7 min for L-Ser-D-FDLA, while 
the L-FDLA-hydrolysate of 1 gave a peak at 9.5 min. 
Antimicrobial Assay. Antimicrobial activity was evaluated by the liquid microculture method 
using round-bottomed 96-well microtiter plates against six bacteria, Bacillus subtilis 
ATCC6633, Micrococcus luteus ATCC9341, Staphylococcus aureus FDA209P JC-1, 
Ralstonia solanacearum SUPP1541, Rhizobium radiobacter NBRC14554, and Escherichia 
coli NIHJ JC-2 and two yeasts Candida albicans NBRC0197 and Saccharomyces cerevisiae 
S100 as indication strains. Tryptic Soy Broth (Difco) and Potato Dextrose Broth (Difco) were 
used for bacteria and yeasts, respectively. Compound 1 and reference drugs, kanamycin sulfate 
for bacteria and amphotericin B for yeasts, were made in 2-fold dilution series along the longer 
side of the plates by sequential transfer of 100 L aliquots between the adjacent wells, to which 
the same amount of medium was pre-dispensed. To each well was added a 100 L suspension 
of the indication strains prepared at 0.5 McFarland (~108 cfu/mL) from a culture at the 
logarithmic growth phase. The solvent vehicle added to the top rows was set at the 0.5% of the 
final culture volume to avoid the effect on the growth of microbes. The plates were incubated 
for 48 h at 37°C for bacteria and at 32°C for yeasts. The tests were done in triplicate and the 
MIC values were read from the lowest drug concentrations at which no growth was observed. 
Cytotoxicity Assay. P388 murine leukemia cells were maintained in RPMI-1640 medium 
containing phenol red, L-glutamine, and HEPES (product no. 189-02145) supplemented with 
10% fetal bovine serum and 0.1 mg/mL gentamicin sulfate. Compound 1 and doxorubicin as a 
reference were serially diluted by a factor of 3.16 (half-logarithmic dilution) in a 96-well round 
bottom microtiter plate. To each well were seeded the cells at a final density of 1×104 cells/well, 
and 200-µL cultures thus made were incubated for 48 h at 37°C in an atmosphere of 5% CO2 
in air with 100% humidity. Viability of the cells was visualized by MTT, added to each well 
as a 50 L solution in phosphate buffered saline without Ca2+ prepared at 1 mg/mL. After 
incubating for 4 h at 37°C, medium was carefully removed by a suction aspirator, and formazan 
dye formed by respiratory reduction by living cells was solubilized by 100 L of DMSO. The 
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absorption at 540 nm was read by a microplate reader to calculate the rate of cell growth 
inhibition at each concentration, and the results of triplicate experiments were plotted on single-
logarithmic charts to deduce IC50 values. 
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Figure S1. UV spectra of labrenzbactin (1) 
(A) MeOH 
 
(B) MeOH – 0.01 M HCl (99:1) 
 
(C) MeOH – 0.01 M NaOH (99:1) 
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Figure S2. IR spectrum of 1 
(ATR) 
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Figure S3. 1H NMR spectrum of 1 (500 MHz, CDCl3–CD3OH (9:1)) 
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Figure S4. 13C NMR spectrum of 1 (125 MHz, CDCl3–CD3OH (9:1)) 
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Figure S5. DEPT135 spectrum of 1 (125 MHz, CDCl3–CD3OH (9:1)) 
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Figure S6. COSY spectrum of 1 (500 MHz, CDCl3–CD3OH (9:1)) 
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Figure S7. HSQC spectrum of 1 (500 MHz, CDCl3–CD3OH (9:1)) 
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Figure S8. HMBC spectrum of 1 (500 MHz, CDCl3–CD3OH (9:1)) 
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Figure S9. NOESY spectrum of 1 (500 MHz, CDCl3–CD3OH (9:1)) 
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Figure S10. 1H NMR spectrum of 1 (500 MHz, DMSO-d6)  
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Figure S11. 13C NMR spectrum of 1 (125 MHz, DMSO-d6)  
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Figure S12. DEPT135 spectrum of 1 (125 MHz, DMSO-d6)  
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Figure S13. COSY spectrum of 1 (500 MHz, DMSO-d6) 
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Figure S14. HSQC spectrum of 1 (500 MHz, DMSO-d6) 
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Figure S15. HMBC spectrum of 1 (500 MHz, DMSO-d6) 
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CHAPTER 4 
 
Isolation and Biosynthesis of an Unsaturated 
Fatty Acid with Unusual Methylation Pattern 
from a Coral-Associated Bacterium 
Microbulbifer sp. C4-6 
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4-1 Background 
Stony corals and their associated bacteria are largely overlooked for natural product 
research. Although stony coral harbor diverse group of microbial community, coral-associated 
bacteria and their natural products have not received considerable attention [1]. To date, a 
handful of new natural products such as pseudoalteromones A and B [2,3], macrolactin V [4], 
and aqabamycins A-G [5] were discovered from soft coral-associated bacteria, but there is no 
report on the new compounds from stony coral-associated bacteria except our previously 
reported compound in chapter 3 [6] (Figure 4-1). 
 
Figure 4-1. Chemical structures of new bioactive compounds from bacteria associated with soft 
corals. 
I decided to undertake HPLC-UV screening for more bacteria associated with stony corals 
after successful isolation and structure determination of labrenzbactin, which is the first natural 
product reported from stony coral-associated bacteria. As described in Chapter 3, in this study 
also I used HPLC-UV-guided fractionation of strain C4-6 which led to the discovery of new 
unsaturated fatty acid with unique methylation pattern.  
HPLC-UV screening was utilized to examine the secondary metabolite production by 
strain C4-6. Strain C4-6 was collected from stony coral of genus Porites and identified as a 
member of genus Microbulbifer. Likewise, for strain C1-1, this strain also screened using three 
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types of seawater-based fermentation media (A3M, A11M and A16). Fermentation media were 
extracted with 1-butanol. Solvent extracts were analyzed by HPLC-UV, and results revealed 
that only A11M medium supported the metabolite production. In HPLC chromatogram, only 
one major peak was observed with retention time at 17.3 min and UV spectrum of the peak 
showed maximum absorbance at 262 nm (Figure 4-2).  
 
Figure 4-2. HPLC analysis of 1-butanol extract of strain Microbulbifer sp. C4-6. 
Microbulbifer is a genus of the Gram-negative bacteria belonging to the class 
Gammaproteobacteria [7]. Members of this genus are frequently isolated from halophilic 
environments including marine solar saltern [8], marine sediments [9], and marine invertebrates 
[10]. The Microbulbifer species are considered to be marine obligate bacteria as they require 
sodium salt for growth [7]. The strain C4-6 was cultured on Marine Agar, YP medium in 
distilled agar and natural seawater. The strain C4-6 showed growth only on Marine Agar and 
YP medium in natural seawater, this result showed that strain C4-6 cannot grow without NaCl 
and thus marine obligate bacterium (Figure 4-3). To date, only two benzoate derivatives were 
isolated from tunicate derived Microbulbifer sp. [11] (Figure 4-4). 
 
Figure 4-3. Colony morphology of Microbulbifer sp. C4-6 on a) Marine Agar, b) YP medium 
(yeast extract 0.1% and peptone 0.5%) in distilled water, c) YP medium in natural seawater. 
c a b 
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Figure 4-4. Chemical structure of bulbiferates A and B isolated from Microbulbifer sp. 
In our continuing investigation of natural products from stony coral-associated bacteria, 
(2Z,4E)-3-methyl-2,4-decadienoic acid (1) was obtained from the culture extract of 
Microbulbifer sp. C4-6 (Figure 4-5). Compound 1 is known as a synthetic compound [12], and 
was used for the synthesis of a retinoid containing the alkylidene butenolide core. Alkylidene 
butenolides constitute the core of many natural and unnatural compounds which display a wide 
range of biological activities. But this is the first finding as a natural product. In addition, 1 is 
biosynthetically unique: it has an uncommon methylation pattern in its carbon chain, derived 
from the C-methylation with L-methionine at a carbon originated from a carbonyl carbon of 
acetate. In this chapter, the isolation and structure determination of 1 and its biosynthetic origin 
proven by the feeding experiments of 13C-labeled precursors are described (Figure 4-5).  
 
 
Figure 4-5. Structure of (2Z,4E)-3-methyl-2,4-decadienoic acid (1). 
4-2 Results and Discussion 
4-2-1 Fermentation and Isolation 
The bacterial strain C4-6 was isolated from a Scleractinian (stony) coral Porites sp. On 
the basis of 16S rRNA gene sequence, this strain was identified as Microbulbifer. Strain C4-6 
was cultured in A11M seawater medium at 30°C for five days, and the whole culture broth was 
extracted with 1-butanol. The extract was consecutively fractionated by normal- and reversed-
phase column chromatographies, followed by HPLC purification to yield compound 1 (Scheme 
4-1). 
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Scheme 4-1. Isolation scheme of (2Z,4E)-3-methyl-2,4-decadienoic acid (1). 
4-2-2 Structure Determination  
The molecular formula of 1 was determined to be C11H18O2 with three degrees of 
unsaturation on the basis of its NMR and HR-ESI-TOFMS (m/z 181.1230 [M - H]-; calcd for 
C11H17O2, 181.1229) data. The UV spectrum of 1 in methanol exhibited an absorption 
maximum at 262 nm. The IR absorption bands at 1678 and 2800~3200 cm-1 suggested the 
presence of carboxyl group. The 1H and 13C NMR data of 1 (Table 4-1) showed the presence 
of 11 carbon signals, which were identified by the assistance of a DEPT135 spectrum as two 
methyls, four sp3 methylenes, three sp2 methines (δC 140.6, 127.7, 115.1), and two sp2 non-
protonated carbons including one carbonyl group (δC 171.3, 153.9). Besides, the 1H NMR 
spectrum showed characteristic resonances, especially for two methyl groups at δH 2.02 (3H, 
s) and 0.90 (3H, t) in the highfield region and for multiple methylene signals, suggesting the 
presence of an alkyl chain. COSY analysis established two separate spin systems, 
H4/H5/H6/H7 and H8/H9/H10. These partial structures were joined by the mutual HMBC 
correlations between H7 and H9. Furthermore, long-range correlations from H11 to C2, C3, 
and C4 and from H2 to C1, C3, and C4 established the carbon connectivity among these 
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carbons to complete the structure of 1 (Figure 4-6). Double bond geometry was determined on 
the basis of NOESY analysis and 3JHH coupling constant. NOE was detected between H2 and 
H11 but not between H2 and H4, reflecting the Z-configuration for the C2-C3 double bond. 
Similarly, NOESY correlations for H4/H6 and H5/H11 reflected the E-configuration for the 
C4–C5 double bond, which was corroborated by 3JHH vicinal coupling constant (JH4,H5 = 15.8 
Hz). 
Table 4-1. 1H and 13C NMR data for compound 1 in CDCl3. 
position Ca H mult (J in Hz)b HMBC
b,c 
1 171.3, C   
2 114.8, CH 5.63, s 1, 3, 4, 11 
3 153.8, C   
4 127.5, CH 7.55, d (15.8) 2, 3, 6, 11 
5 140.3, CH 6.22, dt (15.8, 7.2) 3, 6, 7 
6 33.3, CH2 2.24, dt (7.2, 7.2) 4, 5, 7, 8 
7 28.7, CH2 1.46, m 5, 8, 9 
8 31.4, CH2 1.32d, m 6, 7, 10 
9 22.4, CH2 1.32d, m  
10 13.9, CH3 0.90, t (7.1) 8, 9 
11 21.3, CH3 2.02, s 2, 3, 4 
 
aRecorded at 125 MHz (reference C 77.0).  
bRecorded at 500 MHz (reference H 7.26). 
cHMBC correlations are from proton(s) stated to the indicated carbon. 
dOverlapping signals. 
 
 
Figure 4-6. COSY and key HMBC correlations for 1 
4-2-3 Biosynthesis 
In fungi and certain kinds of bacteria, methyl substituents in the fatty acid carbon chain 
or the polyketide chain are derived from the methyl group of S-adenosylmethionine (SAM) 
(Figure 4-7). For example, anthracimycin is a bioactive decalin-fused tricyclic macrolide 
isolated from Streptomyces species. In actinomycetes, the pendant methyl groups in polyketide 
chain usually derived from methylmalonyl CoA but in some cases like anthracimycin pendant 
methyls were dervived from L-methionine (via SAM) [13,14] (Figure 4-7A and 4-8). This 
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methylation reaction usually occurs at the nucleophilic carbons originated from the methyl 
carbon of acetate (C2) since SAM acts as an electrophilic methyl donor. In most of the bacteria 
including actinomycetes, methyl branching in polyketide chain is derived from methylmalonyl 
CoA, thereby the methylation position must be also the -position (C2) of acetate unit [13]. 
For example, biosynthetic study of erythromycin, showed pendant methyl groups of 6-
deoxyerythronolide B, which is a aglycone precursor of erythromycin were derived from 
propionates (the metabolic precursor of methylmalonate) [15] (Figure 4-7B and 4-9). In 
contrast, methylation at the carbons derived from the carbonyl carbon of acetate (C1) is quite 
unusual in fatty acids and polyketides. This unusual methylation pattern is reported for the 
polyketides of eukaryotic algae dinoflagellates. Some of the methyl groups in dinoflagellate 
compounds are positioned at the carbons derived from the carbonyl carbon of acetate (C1). 
Precursor labeling studies of amphidinolide B indicated that the origin of the methyl carbon is 
not SAM but one carbon fragment derived from the cleavage of another acetate unit [16] 
(Figure 4-7C and 4-10). The only single example of C-methylation with SAM at a carbon 
derived from the carbonyl carbon of acetate (C1; Figure 4-7D) is reported for sphingolipid 
biosynthesis in the yeast, Pichia pastoris [17]. SAM-dependent C-methylation takes place at 
the alkenyl carbon C9 of glucosylceramide, yielding a cationic intermediate, from which 
deprotonation occurs at C9 to give an internal olefin (Scheme 4-2). 
 
 
Figure 4-7. Methylation pattern that can occur in fatty acids and polyketides. 
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Figure 4-8. Biosynthesis of anthracimycin from Streptomyces sp. 
 
Figure 4-9. Biosynthesis of erythromycin from Streptomyces erythraea. 
 
Figure 4-10. Biosynthesis of amphidinolide B from the dinoflagellate Amphidinium sp. 
In the case of 1, methylation at the C3 carbon is inconsistent with the regular methylation 
pattern that occurs in fatty acids synthesized by FAS (fatty acid synthase) or polyketides from 
PKS (polyketide synthase) system of bacterial group. Therefore, the biosynthetic origin of 1 
was investigated by feeding experiments of 13C-labeled precursors (Table 4-2). In order to 
elucidate the biosynthetic origin and incorporation pattern, producing strain C4-6 was cultured 
in the presence of plausible biosynthetic precursors labeled with carbon-13, namely [1-
13C]acetate, and L-[methyl-13C]methionine. Firstly, in order to verify the origin of the carbon 
backbone, [1-13C]acetate was fed to the culture which gave the high enrichment of the carbons 
at C1, C3, C5, C7, and C9 (Figure 4-11 and 12). Feeding experiment with L-[methyl-
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13C]methionine was then carried out. The high level of enrichment was observed only for C11 
in the 13C NMR spectrum, thereby confirming that the methyl group is derived from methionine 
via SAM (Figure 4-11 and 12). In addition to the fungal sphingolipids described above, methyl 
branches with SAM-origin are also found in some bacterial fatty acids like tuberculostearic 
acid, a major constituent of mycobacterial membrane phospholipids [18]. Methylation onto the 
olefinic double bond of oleic acid part in phospholipids is catalyzed by SAM-dependent 
methyltransferase, followed by 1,2-hydride shift and deprotonation, and a subsequent reduction 
of exo-methylene intermediate gives rise to a methyl group [19] (Scheme 4-3). The presence 
of the exo-methylene intermediate was experimentally proved but the enzyme responsible for 
the double bond reduction has not been identified [19]. Based on the C-methylation pattern 
found in the biosynthesis of sphingolipid and tuberculostearic acid, we propose a possible 
mechanism of methylation for compound 1 although further chemical/biochemical 
investigation is required (Scheme 4-4). First, 2,4-decadienoic acid is formed and methylation 
takes place at C3 to give a putative cationic intermediate. The following proton loss from C3 
is likely probable to give directly 1 in a similar fashion to the glucosylceramide biosynthesis. 
Branched chain fatty acids are commonly present in cell membranes, and mono-methylation at 
the iso or anteiso position is the most common [20]. Branching at other positions is less 
common but represents a significant proportion of branched-chain fatty acids in some 
organisms [20]. Tuberculostearic acid (10-methyloctadecanoic acid (18:1me(10)), 10- 
methylhexadecanoic acid (16:1me(10)), and 10-methylnonadecanoic acid (19:1me(10)) are the 
major constituents of the cell wall of Mycobacterium phlei [21]. C9-Methylated 
glucosylceramides also possess a methyl-branching in the middle of the aliphatic carbon chain 
of the sphingosine part. C9-Methylated sphingolipids have not been found from plants and 
animals but are widely produced by many fungi and are thought to play an important role in 
the interaction between fungi and their host organisms. C9-Methylated sphingolipids are also 
found from some marine invertebrates such as sea anemone and starfish although their 
biological function is still unclear in these organisms. C-Methylation at C9 of fungal 
sphingosines is similarly catalyzed by SAM-dependent methyltransferases. The methylation 
takes place at the alkenyl carbon (C9) which is originally derived from the carbonyl carbon of 
an acetate unit: C1 and C2 of sphingosines are derived from L-serine and carbons from C3 to 
C18 are from palmitoyl-CoA. To the best of our knowledge, compound 1 is the first example 
of a simple fatty acid in which the carbonyl carbon of an acetate unit is methylated with SAM 
(Figure 4-7D). 
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Table 4-2. Incorporation of 13C-labeled precursors into 1. 
  relative enrichmenta 
position Cb [1-13C]acetate 
L-[methyl-13C]- 
methionine 
1 171.3 8.99 1.10 
2 114.8 0.91 1.12 
3 153.8 10.13 0.84 
4 127.5 1.00 1.00 
5 140.3 11.19 0.99 
6 33.3 1.15 1.12 
7 28.7 11.35 1.12 
8 31.4 1.19 1.20 
9 22.4 12.01 
 
1.13 
10 13.9 1.37 1.17 
11 21.3 1.20 17.74 
 
aThe 13C signal intensity of each peak in the labeled 1 divided by that of the corresponding signal in the unlabeled, 
normalized to the peak area of C4 to give an enrichment ratio for enriched peak. The numbers in bold type indicate 13C-
enriched atoms from 13C-labeled precursors. 
bRecorded at 125 MHz (reference C 77.0). 
 
 
Figure 4-11. Incorporation of 13C-labeled precursors into 1. 
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Figure 4-12. 13C NMR Spectra of 1 labeled with [1-13C]acetate and L-[methyl-13C]methionine 
(125 MHz, CDCl3). 
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Scheme 4-2. C-Methylation of alkenyl carbon in sphingolipid biosynthesis. 
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Scheme 4-3: Biosynthesis of tuberculostearic acid in Mycobacterium sp. 
 
Scheme 4-4. Possible methylation mechanism for compound 1. 
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4-2-4 Bioactivity 
Compound 1 was not active against Staphylococcus aureus FDA209P JC-1, Micrococcus 
luteus ATCC9341, Bacillus subtilis ATCC6633, Escherichia coli NIHJ JC-2, Ralstonia 
solanacearum SUPP1541, Rhizobium radiobacter NBRC14554, and Candida albicans 
NBRC0197 (MIC >100 μg/mL) but weakly active against Saccharomyces cerevisiae S100 
(MIC 100 μg/mL). 
4-3 Conclusion 
In summary, chemical investigation of Microbulbifer sp. associated with stony coral 
Porites sp. led to the discovery of a unique unsaturated fatty acid, (2Z,4E)-3-methyl-2,4-
decadienoic acid (1) in which the carbon originated from the carbonyl carbon of an acetate unit 
is methylated, providing a quite rare case of C-methylation pattern in fatty acid/polyketide 
biosynthesis. Compound 1 and its (2E,4E)-isomer were reported previously as synthetic 
compounds but this is the first finding of 1 as a natural product [12,22]. In general, bacterial 
FAS catalyze the transfer of a methyl group from SAM to an inactivated double bond of a lipid 
chain, followed by deprotonation of the newly attached methyl group to form compound like 
1. Chemoinformatics insight into functional groups present in 186,000 molecules where natural 
products producing organisms were identified showed that carboxyl group conjugated with 
double bond type functional group like in compound 1 occurred only in 1.30% of molecules 
[23]. This results also showed that such functional group is not common in natural products. In 
addition, the presence of the pendant methyl group in odd number of carbon of fatty acid 
showed unique pattern of methylation occurred in compound 1.  
To date, benzoate derivatives are reported from a tunicate-derived Microbulbifer [11]. 
Therefore, this is the second report on the small molecule from this underexplored taxon. 
According to the genome sequence database, biosynthetic genes for NRPS and siderophore are 
present in Microbulbifer species, which offer researchers to utilize bacteria of this genus to 
quest for new bioactive compounds in the future.  
The phylum Proteobacteria is a potential source of novel bioactive compounds amongst 
marine bacteria but have received considerably less attention than actinobacteria. 
Proteobacteria in marine environment usually found in the association with corals, sponges and 
mollusks. Within the phylum Proteobacteria, the classes of Alpha-, Gamma-, Beta-, Delta-, and 
Epsilonproteobacteria comprise 32, 13, 2, 2 and 0.4% of all bacteria in the water column, 
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respectively [24]. Gammaproteobacteria is one of the most diverse group of bacteria and a rich 
source of marine natural products with well-established genus Pseudoalteromonas, Vibrio and 
Pseudomonas. Although members of the Alphaproteobacteria seem to be the most abundant in 
marine environments, Gammaproteobacteria is the most successfully cultured [24]. But total 
number of natural products from this class of bacteria is relatively small [25-35] (Figure 4-13). 
Fewer number of bioactive compounds have been discovered from marine Proteobacteria than 
actinobacteria and fungi, possibly because these have not been studied extensively for their 
capability to produce secondary metabolites or they do not possess biosynthetic genes as 
commonly as Gram-positive bacteria.  
 
Figure 4-13. Structures of compounds from marine Gammaproteobacteria. 
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Fatty acids are carboxylic acids with a long aliphatic alkyl chains and they are ubiquitous 
in nature. Marine fatty acids are obtained from a variety of sources, including marine fishes, 
sponges, corals, sea cucumbers, limpets, and microorganisms. In past decades, marine derived 
unsaturated fatty acids have attracted considerable interest because of their structural diversity, 
potential biological activities and nutritional functions [36]. Although bacteria are one of the 
predominant microbiota of marine environments, only handful of fatty acids derivatives were 
reported from them [37-40] (Figure 4-14).  
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Figure 4-14. Structures of fatty acid derivatives from marine derived bacteria. 
4-4 Experimental Section 
General Experimental Procedures. The UV spectrum was recorded on a Shimadzu UV-1800 
spectrophotometer. The IR spectrum was measured on a Perkin-Elmer Spectrum 100. NMR 
spectra were obtained on a Bruker AVANCE 500 spectrometer in CDCl3 using the signals of 
the residual solvent proton (δH 7.26) and carbon (δC 77.0) as internal standards. HR-ESI-
TOFMS were recorded on a Bruker micrOTOF focus. Sodium [1-13C]acetate was purchased 
from Cambridge Isotope Laboratories, Inc., and L-[methyl-13C]methionine from Sigma-Aldrich 
Co. LLC. 
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Microorganism. Strain C4-6 was isolated from a cultured stony coral (Porites sp.) obtained 
from an aquarium vendor in Nagasaki, Japan. The coral specimen was washed with 70% 
ethanol and then washed with sterile natural seawater. A fragment of the coral (ca 1 g) was 
homogenized by mortar and pestle with an equal amount of sterile natural seawater (1 mL), 
and 10-fold serial dilution was carried out up to 10-5 and 0.1 mL of each dilution was spread 
onto Marine Agar 2216 (Difco). The plates were kept at 23°C, and a single colony was 
repeatedly transferred onto the same agar medium to obtain the pure isolate of strain C4-6. The 
strain was identified as a member of genus Microbulbifer on the basis of 99.0% similarity in 
the 16S rRNA gene sequence (1405 nucleotides; DDBJ accession number LC456787) to 
Microbulbifer variabilis Ni-2088T (accession number AB167354). 
Fermentation. The producing strain C4-6 was maintained on Marine Agar 2216 (Difco). A 
single colony of strain C4-6 was inoculated into a 500 mL K-1 flask containing 100 mL of 
Marine Broth 2216 (Difco) as a seed culture. The seed culture was incubated at 30°C on a 
rotary shaker at 200 rpm for 2 days. Three mL of seed culture was inoculated into twenty-five 
500 mL K-1 flasks each containing 100 mL of A11M production medium, which consists of 
glucose 0.2%, soluble starch 2.5%, yeast extract 0.5%, polypeptone (Wako Pure Chemical 
Industries, Ltd.) 0.5%, NZ-amine (Wako Pure Chemical Industries, Ltd.) 0.5%, CaCO3 0.3%, 
and Diaion HP-20 (Mitsubishi Chemical Co.) 1% in natural seawater (collected from Toyama 
Bay, Toyama, Japan). The pH of the medium was adjusted to 7.0 before sterilization. The 
inoculated flasks were incubated at 30°C on a rotary shaker at 200 rpm for 5 days. 
Extraction and Isolation. After fermentation, 100 mL of 1-butanol was added to each 
production culture flask, and the flasks were allowed to shake for 1 h on a rotary shaker at 200 
rpm. The mixture was centrifuged at 6000 rpm for 10 min in order to separate organic layer 
and aqueous layer. The organic layer was concentrated in vacuo to afford 3.2 g of extract from 
2.5 L of production culture. The extract was fractionated by silica gel column chromatography 
with a step gradient of CHCl3-MeOH (1:0, 20:1, 10:1, 4:1, 2:1, 1:1, and 0:1 v/v). Fraction 3 
(10:1) was concentrated to give a brown oil (646 mg), which was then fractionated by reversed-
phase ODS column chromatography with a gradient of MeCN-0.1% HCO2H (2:8, 3:7, 4:6, 5:5, 
6:4, 7:3, and 8:2 v/v). Fraction 6 (7:3) was concentrated and extracted with EtOAc. The organic 
layer was dried over anhydrous Na2SO4, filtered, and concentered to give a semi-pure material 
(21 mg). Final purification was achieved by preparative HPLC (Cosmosil Cholester 5 µm, 10 
x 250 mm, 4 mL/min, UV detection at 254 nm) with an isocratic elution of MeCN-0.1% 
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HCO2H solution (50:50) to yield (2Z,4E)-3-methyl-2,4-decadienoic acid (1, 8.0 mg, tR 20.5 
min). 
(2Z,4E)-3-Methyl-2,4-decadienoic acid (1): colorless amorphous solid; UV (MeOH) λmax (log 
ε) 262 (4.16) nm; IR (ATR) νmax 2952, 2923, 2852, 2585, 1678, 1662 cm−1; 1H and 13C NMR 
data, see Table 4-1; HR-ESI-TOFMS m/z 181.1230 [M - H]- (calcd for C11H17O2, 181.1229). 
Feeding Experiment. Feeding experiments were carried out using 13C-labeled precursors, 
sodium [1-13C]acetate and L-[methyl-13C]methionine. The fermentation, extraction and 
purification of labeled compounds were performed in the same manner as describe for the 
unlabeled compound. After 24 h of the inoculation into the production medium from the seed 
culture, supplementation of 13C-labeled precursors was commenced and carried out for four 
times at 24 h interval. After further 24 h incubation, the whole culture broth was extracted with 
1-butanol. 
1) Sodium [1-13C]acetate: 13C-Labeled 1 (1.6 mg) was obtained from 1 L of culture 
supplemented with sodium [1-13C]acetate (total 800 mg; 20 mg × 10 flasks × 4 days). The 13C 
NMR spectrum showed enriched signals at δ 170.2, 153.8, 140.3, 28.7, and 22.4. 
2) L-[Methyl-13C]methionine: 13C-Labeled 1 (0.9 mg) was obtained from 1 L of culture 
supplemented with L-[methyl-13C]methionine (total 80 mg; 2.0 mg × 10 flasks × 4 days). The 
13C NMR spectrum showed an enriched signal at δ 21.3. 
Antimicrobial Assay. Antimicrobial activity was evaluated by the liquid microculture method 
using round-bottomed 96-well microtiter plates against six bacteria, Bacillus subtilis 
ATCC6633, Micrococcus luteus ATCC9341, Staphylococcus aureus FDA209P JC-1, 
Ralstonia solanacearum SUPP1541, Rhizobium radiobacter NBRC14554, Escherichia coli 
NIHJ JC-2, and two yeasts Candida albicans NBRC0197 and Saccharomyces cerevisiae S100 
as indication strains. Tryptic Soy Broth (Difco) and Sabouraud Dextrose Broth (Difco) were 
used for bacteria and yeasts, respectively. Compound 1 and reference drugs, kanamycin sulfate 
for bacteria and amphotericin B for yeasts, were made in 2-fold dilution series along the longer 
side of the plates by sequential transfer of 100 L aliquots between the adjacent wells, to which 
the same amount of medium was pre-dispensed. To each well was added a 100 L suspension 
of the indication strains prepared at 0.5 McFarland (~108 cfu/mL) from a culture at the 
logarithmic growth phase. The solvent vehicle added to the top rows was set at the 0.5% of the 
final culture volume to avoid the effect on the growth of microbes. The plates were incubated 
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for 48 h at 37°C for bacteria and at 32°C for yeasts. The tests were done in triplicate and the 
MIC values were read from the lowest drug concentrations at which no growth was observed. 
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Figure S1. UV spectrum of (2Z,4E)-3-methyl-2,4-decadienoic acid (1)  
 
 
Figure S2. High resolution ESI-TOF mass spectrum of 1 
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Figure S3. IR spectrum of 1 
(ATR) 
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Figure S4. 1H NMR spectrum of 1 (500 MHz, CDCl3) 
 
 
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
pp
m
0.881
0.895
0.909
1.328
1.459
2.022
2.195
2.197
2.211
2.225
2.239
2.241
5.628
6.163
6.177
6.192
6.194
6.209
6.223
7.519
7.551
3.091
4.382
2.121
3.074
2.079
1.000
1.010
1.001
104 
 
Figure S5. 13C NMR spectrum of 1 (125 MHz, CDCl3) 
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Figure S6. DEPT135 spectrum of 1 (125 MHz, CDCl3) 
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Figure S7. COSY spectrum of 1 (500 MHz, CDCl3) 
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Figure S8. HSQC spectrum of 1 (500 MHz, CDCl3) 
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Figure S9. HMBC spectrum of 1 (500 MHz, CDCl3) 
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Figure S10. NOESY spectrum of 1 (500 MHz, CDCl3) 
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CHAPTER 5 
 
Two Antibacterial and PPARα/γ-Agonistic 
Unsaturated Keto Fatty Acids from a Coral-
Associated Bacterium Micrococcus sp. C5-9 
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5-1 Background 
After successful isolation and characterization of labrenzbactin and unsaturated fatty acid 
with a unique methylation pattern from Labrenzia and Microbulbifer as described in Chapter 
3 and 4, respectively, I found marine obligate bacteria isolated from stony corals are the 
potential source of bioactive compounds. Previous studies in Chapter 3 and 4, substantiated 
that new types of bacteria are an intriguing source for the natural product screening program 
because they have not been exploited yet, even they contain biosynthetic gene clusters for some 
interesting group of molecules. So there is still a high chance of finding new bioactive 
molecules from such new group of bacteria. A new group of bacteria may carry genome for a 
new type of biosynthetic pathways resulting in the production of new bioactive molecules. 
However, in this chapter I worked with a common type of bacteria, Micrococcus, which can 
be readily isolated from marine as well as non-marine sources and NaCl is not essential for 
growth. Basically, if we work with very common type or overexploited group of bacteria, there 
is a high risk of finding already known compound. But I decided to undertake HPLC-UV 
screening of Micrococcus sp. C5-9 using different type of media varying in nutrient 
compositions because I think bacteria from the common taxonomic group could be interesting 
for the screening program if they are isolated from unexplored sources such as stony corals, 
which are not exploited for isolation of natural products as well as isolation of associated 
bacteria for the natural product screening program. 
Marine actinobacteria are considered as a potential source for novel natural products with 
high structural diversity, unique biological activity, and molecular mode of action, beneficial 
to drug development [1-3]. Actinobacteria in marine environments are mostly found in 
association with higher organisms such as fish, sponges, corals, mollusks, ascidians, seaweeds, 
and mangroves, and have kept attracting attention due to their ability to produce various 
bioactive compounds [2,4]. Among the isolation sources for marine actinobacteria, substantial 
amounts of studies were devoted to sponges from which a wide range of actinobacterial species 
were found to produce intriguing natural products [5]. Corals, another large group of marine 
invertebrates, also harbor diverse symbiotic or associating microorganisms [6], however only 
a handful of natural products such as streptochloritides [7], nahuoic acids B-E [8], pteridic 
acids C-G [9], and octalactins A and B [10] were obtained from actinobacteria associated with 
soft corals (Figure 5-1). There is no report indeed on natural products from actinobacteria 
residing in stony corals. 
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Figure 5-1. Bioactive compounds from actinobacteria associated with soft corals. 
Actinomycetes of the genus Micrococcus are Gram-positive, aerobic, and non-motile 
cocci. Unlike the majority of actinomycetes, they typically form tetrad clusters but not hyphae 
[11]. Micrococcus is ubiquitous in distribution and, similar to other actinomycetes, marine 
Micrococcus are commonly associated with marine invertebrates such as sponges and corals 
[4,12,13]. Distinct classes of natural products have been isolated from sponge-associated 
Micrococcus, including glycosylated glycerolipid [14,15], cyclic peptide [16], xanthone 
glycoside [17], and halogenated diphenyl ether [15] (Figure 5-2). Until now, however, no 
natural products are known from coral-associated Micrococcus. Limazepines [18], micrococcin 
[19], neoberninamycin [20], and iso-branched octadecenoic acids [21] are the notable examples 
of natural products isolated from Micrococcus from various sources (Figure 5-3). 
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Figure 5-2. Natural products isolated from Micrococcus sp. collected from sponges. 
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Figure 5-3. Natural products isolated from Micrococcus sp. 
In this chapter, the fermentation, isolation, structure determination, and bioactivity of two 
new keto fatty acids, (6E,8Z)-5-oxo-6,8-tetradecadienoic acid (1) and its (6E,8E)-isomer (2) 
from a coral-associated actinomycete Micrococcus sp. C5-9 are described. 
5-2 Results and Discussion 
UV-chemical screening was employed to check the secondary metabolites production by 
Micrococcus sp. C5-9 associated with a stony coral. Three type of fermentation media (A3M, 
A11M and A16) were used for screening of metabolites. Strain C5-9 produced metabolites 
significantly only in medium A16, so this media was selected for further large scale 
fermentation and isolation of compound. This strain produced more than one peaks in A16 
medium with similar UV profile but in this study I was able to obtain peaks A and B in 
sufficient amount for structure determination and bioactivity assays. Peaks A and B were eluted 
in 16.2 and 16.6 min, respectively (Figure 5-4). The UV spectra of peaks A and B showed 
absorption maxima at 277 and 275 nm, respectively.  
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Figure 5-4. HPLC analysis of 1-butanol extract of producing strain Micrococcus sp. C5-9. 
This strain readily grows on Marine Agar and other media without NaCl such as Muller-
Hinton Agar prepared in distilled water. From this result, I concluded that this strain is 
halotolerant (Figure 5-5). Micrococcus sp. are commonly encountered bacteria in the nature 
but I selected this strain for my study because strain was collected from a stony coral, which is 
unexplored source for natural products discovery. 
 
Figure 5-5. Colony morphology of Micrococcus sp. C5-9 on Marine Agar. 
5-2-1 Fermentation and Isolation 
The producing strain C5-9 was obtained from stony coral Catalaphyllia sp., and identified 
as a member of the genus Micrococcus by 16S rRNA gene sequence analysis. The HPLC-UV 
analysis of fermentation broth of strain C5-9 indicated the presence of metabolites showing 
UV absorption around 275 nm. Large-scale shaking culture (2.9 L) was carried out in A16 
seawater medium at 30°C for five days to obtain adequate amounts of compounds for structure 
determination and bioassay. Fermentation broth was extracted with 1-butanol, and the extract 
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was fractionated by solvent/solvent partitioning. Following ODS column chromatography and 
isocratic reversed-phase preparative HPLC gave 1 (3.7 mg) and 2 (2.4 mg) (Scheme 5-1). 
 
Scheme 5-1. Isolation of 1 and 2. 
5-2-2 Structure Determination 
(6E,8Z)-5-Oxo-6,8-tetradecadienoic acid (1) was obtained as a pale yellow amorphous 
solid (Figure 5-6). The molecular formula was determined to be C14H22O3 on the basis of its 
NMR and HR-ESITOFMS (m/z 261.1453 [M+Na] +; calcd for C14H22O3Na, 261.1461) data. 
The UV spectrum of 1 in methanol exhibited an absorption maximum at 277 nm. The IR 
absorption bands at 1708 and 2800~3400 cm-1 were suggestive of the carbonyl and hydroxy 
functionalities. The 13C NMR and DEPT spectra of 1 (Table 5-1) displayed 14 carbon signals, 
including one methyl, seven sp3 methylenes, four sp2 methines (δC 143.1, 137.5, 129.1, and 
126.8), one carboxyl carbon (δC 178.2), and one deshielded aldehyde or ketone carbon signal 
(δC 199.8). Four degrees of unsaturation indicated by 13C signals were consistent with that 
calculated from the molecular formula, which indicated that 1 has a linear structure. The 1H 
NMR spectrum showed characteristic resonances for a terminal methyl group at δH 0.89 (3H, 
t) in the shielded region and for multiple methylene signals, suggesting the presence of an alkyl 
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chain. COSY analysis established three spin systems, one from H2 to H4, a seven-carbon 
fragment from H6 to H12, and an ethyl fragment H13/H14. These partial structures were joined 
into one linear structure by HMBC correlations from H3, H4, H6, and H7 to C5, H14 to C12, 
and H11 to C13. Finally, a correlation from H2 and H3 to C1 connected the carboxyl group at 
C2 to complete the structure of 1 (Figure 5-7). The geometry of the double bonds was 
determined as E at C6 and Z at C8 based on the 1H-1H coupling constants JH6,H7=15.3 Hz and 
JH8,H9= 10.8 Hz, respectively. 
 
Figure 5-6. Structures of (6E,8Z)- and (6E,8E)-5-oxo-6,8-tetradecadienoic acids (1 and 2). 
 
Figure 5-7. COSY and key HMBC correlations for 1 and 2. 
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Table 5-1: 1H and 13C data for compounds 1 and 2 in CDCl3. 
 1  2 
position δCa δH mult (J in Hz)b HMBCb,c  δCa δH mult (J in Hz)b HMBCb,c 
1 178.2, C    177.7, C   
2 32.9, CH2 2.44, m 1, 3, 4   32.9, CH2 2.42, m 1, 3, 4 
3 19.1, CH2 1.97, m 1, 2, 4, 5  19.1, CH2 1.96, quint (7.0) 1, 2, 4, 5 
4 39.6, CH2 2.66, t (6.6) 2, 3, 5  39.0, CH2 2.65, t (7.1) 2, 3, 5 
5 199.8, C    199.8, C   
6 129.1, CH 6.15, d (15.3) 4, 5, 8  127.6, CH 6.07, d (15.6) 4, 5, 8 
7 137.5, CH 7.51, dd (15.3, 11.7) 5, 6, 8, 9  143.5, CH 7.15, dd (15.6, 9.5) 5, 8, 9 
8 126.8, CH 6.10, dd (11.7, 10.8) 5, 6, 7, 10  128.7, CH 6.15, dd (15.6, 9.5)g 6, 7, 10 
9 143.1, CH 5.92, dt (10.8, 7.9) 7, 8, 10, 11  146.2, CH 6.18, dt (15.6, 6.3)g 7, 10, 11 
10 28.3d, CH2 2.31, q (7.5) 8, 9, 11, 12  33.1, CH2 2.18, dt (6.3, 7.2) 8, 9, 11, 12 
11 29.0d, CH2 1.43, quint (7.1) 9, 10, 12, 13  28.3, CH2 1.43, quint (7.2) 10, 12, 13 
12 31.4, CH2 1.32e, m 10, 11, 13  31.4, CH2 1.29f, m  11, 13 
13 22.5, CH2 1.30e, m 12, 14  22.4, CH2 1.31f, m 12 
14 14.0, CH3 0.89, t (6.8) 12, 13  14.0, CH3 0.89, t (6.9) 12, 13 
 
aRecorded at 125 MHz (reference δC 77.0).  
bRecorded at 500 MHz (reference δH 7.26). 
cHMBC correlations are from proton(s) stated to the indicated carbon. 
dAssignment interchangeable. 
e,fOverlapping signals. 
gDetermined by NMR simulation. 
The molecular formula of 2 was also determined to be C14H22O3 on the basis of its NMR 
and HR-ESI-TOFMS (m/z 261.1458 [M+Na] +; calcd for C14H22O3Na, 261.1461) data. The 1H 
and 13C NMR spectra of 2 displayed similar feature to those for 1 except five 1H/13C resonances 
from C6 to C10, which indicated the structural difference between 1 and 2 to be in the double 
bond geometries. In fact, the composition of 14 carbon signals, the carbon connectivity, and 
the sites of functional groups in 2 proved to be completely the same as those in 1 by the 
interpretation of 13C, DEPT, COSY, and HMBC correlations (Figure 5-7) except double bond 
configuration at C8.  
5-2-3 Determination of Configuration for the C8-C9 Double Bond  
While an E-configuration at C6 was evident from the coupling constant JH6,H7 = 15.6 Hz, 
JH8,H9 was unable to read from the multiplicity pattern of H8 and H9, due to the intense second 
order effects caused by a signal overlap of these resonances (H 6.15 and 6.18, respectively). 
Although the E-geometry at C8 was circumstantially obvious and supported by the deshielded 
allylic carbon C10 (C 33.1 for 2 v.s. 28.3 for 1), a decisive evidence was acquired from spin-
system simulations using a software ‘nmrpeak’ [22], which gave the best matching to the 
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experimentally obtained 1H NMR spectrum with the setting of 3JH8,H9 = 15.6 Hz and 3JH7,H8 = 
9.5 Hz (Figure 5-8). Thus, the C8 geometry was unambiguously determined to be E. 
 
Figure 5-8 Spin-system simulation for the C8-C9 double bond of 2. 
Coupling constants (J) and chemical shifts (δ) can be directly acquired in first order 
spectra. However, second order spectra are more complex and their interpretation is much more 
complicated [23]. First-order spectra obey all general rules concerning the splitting, intensity 
distribution and integration of the peaks [23]. To acquire a first order spectrum, the chemical 
shift difference (Δv) between the coupled protons in hertz has to be much larger than the 
coupling constants (J) [24]. If Δv/J is lesser than 5 then second order effects appear. When 
Δv/J is less than 1 then second order effects become very noticeable and often preventing 
detailed manual interpretation of multiplets [24]. In this situation, quantum mechanical 
simulation and adjustment of NMR parameters (chemical shifts and J values) to match the 
observed pattern and intensities of NMR lines is the only option to analyze the data [25]. 
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The effects of spectrometer field strength on the ability to resolve NMR coupling 
information is illustrated in the set of spectra of ethylbenzene, plotted at a constant Hz scale 
(Figure 5-9). The aromatic signals go from nearly a singlet at 60 MHz to a reasonably resolved 
set of peaks at 600 MHz. This increase in information content and greater ease of interpretation 
of NMR spectra at higher magnetic field strength is the main justification for the additional 
expense of more powerful magnets [24]. 
 
Figure 5-9. The effects of spectrometer field strength on the ability to resolve NMR coupling 
information [24]. 
A very good example of second order spectra is provided by the compound below (Figure 
5-10). For the BrCH2CH2O group, two methylenes at δH 3.48 and δH 3.81 (c and d) have a 
relatively large chemical shift separation, and they form noticeable triplets, although with a 
little leaning. For the CH3OCH2CH2O group (a and b) the chemical shift between the CH2 
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groups is very small, and the signals are a complicated multiplet with only a vague resemblance 
to a triplet and resulted in second order spectra [24].  
 
Figure 5-10. Example of second order spectrum [24]. 
5-2-4 Bioactivity 
Compounds 1 and 2 inhibited the growth of Tenacibaculum maritimum NBRC16015, a 
causative agent of skin infection of marine fish, and Rhizobium radiobacter NBRC14554, a 
causative agent of crown gall disease of plant. The MIC values for 1 against T. maritimum and 
R. radiobacter were 50 and 6.2 µg/mL, respectively, while 2 was more potent against T. 
maritimum with MIC 12.5 µg/mL and less so against R. radiobacter with MIC 50 µg/mL, 
presenting an interesting contrast (Table 5-2). No appreciable antimicrobial activity was 
observed for both compounds against bacterial strains of Micrococcus luteus ATCC9341, 
Staphylococcus aureus FDA209P JC-1, and Escherichia coli NIHJ JC-2, and yeast strains of 
Candida albicans NBRC0197 and Saccharomyces cerevisiae S100, nor cytotoxicity against 
murine leukemia P388 cells at 100 µM.  
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Table 5-2. Antimicrobial activity of 1 and 2 
 MIC (μg/mL) 
Microorganisms 1 2 
Micrococcus luteus ATCC9341 >100  >100 
Staphylococcus aureus FDA209P JC-1 >100 >100 
Escherichia coli NIHJ JC-2 >100 >100 
Rhizobium radiobacter NBRC14554       6.2     50 
Tenacibaculum maritinum NBRC16015     50 12.5 
Candida albicans NBRC0197 >100 >100 
Saccharomyces cerevisiae S100 >100 >100 
 
Additionally, compounds 1 and 2 were evaluated for agonist activity to peroxisome 
proliferator-activated receptors (PPARs), because similar oxo-fatty acids are known to act as 
PPAR agonist [26]. PPARs are ligand-activated transcription factors, playing key roles in lipid 
and carbohydrate metabolism [27,28]. PPAR upregulates lipid uptake and -oxidation of fatty 
acids, whereas PPAR promotes adipocyte differentiation and adipokine production in adipose 
tissues to improve insulin-sensitivity in diabetic patients [29-31]. Owing to these physiological 
functions in energy metabolism, PPARs are the molecular targets of metabolic disorders [32]. 
To assess the PPAR isoform specificity of 1 and 2, three reporter cell lines that express 
luciferase gene in response to PPARα, PPARβ/, and PPARγ agonists were used. The agonist 
activity was determined as a relative potency to the positive controls, WY14643 for PPARα, 
GW0742 for PPARβ/, and troglitazone for PPARγ. Both 1 and 2 induced activations of 
PPARαand PPARγ transcription but were not effective against PPARβ/ (Figure 5-11). 
Overall, 1 was lesser potent than 2, indicating that the geometry at C8 may play an important 
role in the binding to PPARs. 
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Figure 5-11. PPAR activation by compounds 1 and 2. 
Peroxisome proliferator-activated receptors (PPARs) are ligand activated transcription 
factors, belongings to the superfamily of nuclear hormone receptors [33]. In mammals, three 
different isoforms of PPARs have been described yet: PPARα, PPARβ/δ, and PPARγ [33]. 
PPARα was the first identified member, whereas PPAR β/δ is the least described isoform [33]. 
PPARα mainly expressed in the high energy demanding tissues (liver, heart, kidney and 
muscles) and show high rates of β-oxidation of fatty acids [28]. Similarly, PPAR-β/δ is 
ubiquitously expressed in humans, whereas in mice it is expressed to a higher extent in the 
gastrointestinal duct [28]. PPAR-γ is expressed at high levels in the adipose tissue [28] (Figure 
5-12). 
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Figure 5-12. The physiological roles of PPARs. 
PPAR agonists or activators, are drugs or chemicals that binds to the and activate 
peroxisome proliferator-activated receptor [34]. They are utilized for the treatment of 
metabolic syndroms, dyslipidemia and type II diabetes [35]. Fibrates and thiazolidinediones 
(TZDs) are used to treat these conditions by selectively activating PPARα and PPARγ, 
respectively [35]. Fibrates activate PPARα and reduce plasma triglycerides, and raise plasma 
HDL cholesterol (HDLc) levels [36]. Similarly, TZDs activate PPARγ and reduce glucose 
levels, improve insulin sensitivity, and can improve lipid homeostasis [37]. Many natural and 
synthetic fatty acid derivatives act as PPAR agonist and can play important role in the treatment 
of incidence of metabolic syndrome but they have severe side effects [34,38] (Figure 5-13, 14, 
15, 16 and 17). So there is high demand of natural products which can acts as potent PPAR 
agonist without severe side effects.  
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Figure 5-13. Natural and synthetic activators for PPARs. 
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Figure 5-14. Natural activators for PPAR. 
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Figure 5-15. Synthetic PPARα activators. 
 
Figure 5-16. Synthetic PPARγ activators. 
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Figure 5-17. Synthetic PPARβ/δ activator. 
5-3 Conclusion 
In summary, UV-chemical screening of coral-associated bacterium Micrococcus sp. C5-
9 led to the discovery of two new unsaturated keto fatty acids, (6E,8Z)-5-oxo-6,8-
tetradecadienoic acid (1) and its (6E,8E)-isomer (2). Compounds 1 and 2 showed selective 
antibacterial activity against a plant pathogen R. radiobacter and a fish pathogen T. maritimum, 
respectively. In addition, both 1 and 2 displayed agonistic activity against PPARα and PPARγ. 
Compounds similar to 1 and 2 showed antibacterial and antifungal activities. We do not know 
the exact role of compounds 1 and 2 in the nature but compounds 1 and 2 showed antibacterial 
activity against pathogenic bacteria in in-vitro assay so we can speculate that these compounds 
also may play important role to protect corals from pathogenic bacteria in nature. 
Fatty acids are ubiquitous metabolites present in all organisms. They are organic 
compounds characterized by the presence of a carboxyl group (-COOH) at the one end and a 
methyl group at the other end. Some unusual fatty acids have two adjacent double bonds 
separated by more than one methylene group, and they are termed polymethylene-interrupted 
fatty acids [39]. The structures of fatty acids can be more complicated because they can have 
branched chains, an odd number of carbon atoms, or an array of other functional groups, 
containing acetylenic bonds, epoxy, hydroxy, or keto groups, and ring structures (cyclopropane, 
cyclopropene, cyclopentene, furan, and cyclohexyl) [39]. Recently, fatty acids have drawn 
significant attention because of their nutritional, cosmetic, and pharmaceutical importance [40]. 
Two isomeric keto fatty acids, (7E)-9-oxohexadecenoic acid and (10E)-9-
oxohexadecenoic acid were isolated from the marine algae Chaetoceros karianus, and displyed 
dual PPAR α/γ agonist activity [26]. Majusculoic acid, a cyclopropane containing fatty acid 
isolated from an unidentified cyanobacterial mat assemblage, exhibited antifungal activity 
against Candida albicans with MIC value of 8 µM [41]. Acetylenic fatty acid, named 
scleropyric acid, was isolated from the twigs of Scleropyrum wallichianum, and exhibited 
antiplasmodial activity with an IC50 of 7.2 µg/mL against a K1 multidrug-resistant strain of 
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Plasmodium falciparum and showed antimycobacterial activity with an MIC value of 25 
µg/mL [42]. Pseudomonas aeruginosa PR3 was found to convert linoleic acid to a new 
compound, (E)-9,12,13-trihydroxyoctadec-10-enoic acid (THOD). THOD displayed anti-plant 
pathogenic fungal activities [43]. Chemical investigation of of culture broth of Pseudozyma 
focculosa led to the discovery of two new fatty acids, (9Z)-9-heptadecenoic acid and (9Z)-6-
methyl-9-heptadecenoic acid. These compounds showed antifungal activity [44]. A new furan 
containing fatty acid, plakorsin B was isolated from the Taiwanese marine sponge Plakortis 
simplex. Plakorsin B showed against COLO- 250 and KB-16 cells with IC50 values of 0.28 
µg/mL and 3.43 µg/mL, respectively [45]. 12-methyltetradecanoic acid was isolated from 
endophytic Gram-negative bacterium Stenotrophomonas maltophilia has been shown to inhibit 
appressorium formation in the rice pathogen, Magnaporthe oryzae [46]. Polymethylene-
interrupted fatty acid was isolated from gorgonian coral Eunicea succinea, (5Z,9Z)-14-methyl-
5,9-pentadecadienoic acid. This compound was active against Gram-positive bacteria such as 
Staphylococcus aureus and Streptococcus faecalis [47] (Figure 5-18). 
 
Figure 5-18. Examples of bioactive fatty acids from various sources. 
α-Keto fatty acids are characterized by the presence of a ketone group at α-position of 
carboxylic acids. They are present in all living cells and play crucial roles in the biological 
system as they are involved in the Krebs cycle and glycolysis [48]. In contrast, keto fatty acids 
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bearing a ketone group in the middle of the carbon chain are relatively limited in their 
distribution in nature. Many of such natural keto fatty acids were found from plants, mainly as 
a constituent of seed oil [49-57]. Among them, rabdosia acids [58] and (10E,12E)-9-oxo-10,12-
octadecadienoic acid [59] are the plant keto fatty acids containing the dienone moiety with 
trans-, trans-configuration, but congeners with trans-, cis-configuration have not been found 
from nature, until the present work (Figure 5-19). Some of the keto fatty acids of plant-origin 
are shown to exhibit pharmaceutically important activity. (9E,11E)-13-Oxo-octadecadienoic 
acid is a PPARα activator found in tomato juice. This keto fatty acid decreases plasma and 
hepatic triglyceride in obese diabetic mice by activating PPARα transcription [60]. (10E,12E)-
9-Oxo-octadecadienoic acid isolated from eggplant calyx induces apoptosis in human ovarian 
cancer cells, leading to cell death [61]. One example of keto fatty acid from the animal kingdom 
is (E)-9-oxo-2-decenoic acid, a sex pheromone found in the royal jelly. Queen honey bees use 
this fatty acid to control the activity of worker bees [62]. (E)-7-Oxo-11,13-tetradecadienoic 
acid is another example of insect-origin, identified from hair pencils of male Amauris 
butterflies (Amauris albimaculata), which is supposed to be a precursor material for the 
butterfly pheromone [63]. Furthermore, 4-oxo-2-alkenoic fatty acids were characterized as 
antimicrobial metabolites from an actinomycete [64] and a Basidiomycete fungus [65]. In 
addition, long-chain saturated fatty acids possessing a keto group were detected in the solvent 
extract of Legionella by GC-MS analysis [66]. Fatty acid components in fresh water-derived 
Micrococcus species was comprehensively analyzed [67], but keto fatty acids like compounds 
1 and 2, bearing a dienone system, are unprecedented as microbial metabolites. 
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Figure 5-19. Natural keto fatty acids of various origins. 
5-4 Experimental Section 
General Experimental Procedures. UV and IR spectra were recorded on a Shimadzu UV-
1800 and a Perkin-Elmer Spectrum 100 spectrophotometers, respectively. NMR spectra were 
obtained on a Bruker AVANCE 500 spectrometer in CDCl3 using the signals of the residual 
solvent protons (δH 7.26) and carbons (δC 77.0) as internal standards. HR-ESI-TOFMS were 
recorded on a Bruker micrOTOF focus. 
Microorganism. Strain C5-9 was collected from a stony coral, Catalaphyllia sp., obtained 
from an aquarium vendor in Osaka, Japan. A piece of the coral specimen (ca. 1 g) was surface-
sterilized by washing with 70% ethanol, followed by rinsing with sterile natural seawater. The 
coral piece was homogenized by mortar and pestle with an equal volume of sterile natural 
seawater (1 mL), and the resulting suspension was serially diluted by 10-fold up to 10-5. One-
hundred L aliquots of each dilution were spread onto Marine Agar 2216 (Difco), and the agar 
plates were cultivated at 23°C for 2 days. Single colonies thus emerged on the plates were 
transferred onto a new agar medium to obtain pure isolates. One of these isolates, coded as C5-
9, was identified as a member of genus Micrococcus on the basis of 99.9% similarity in the 
16S rRNA gene sequence (1395 nucleotides; DDBJ accession number LC498624) to 
Micrococcus yunnanensis YIM 65004T (accession number FJ214355). 
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Fermentation. Strain C5-9 was maintained on Marine Agar 2216 (Difco). A loopful of strain 
C5-9 was inoculated into a 500 mL K-1 flask containing 100 mL of Marine Broth 2216 (Difco) 
as a seed culture. The seed culture was incubated at 30°C on a rotary shaker at 200 rpm for 2 
days. Three mL each of seed culture was inoculated into twenty-nine 500 mL K-1 flasks 
containing 100 mL of A16 production medium, which consists of glucose 2%, Pharmamedia 
(Traders Protein, Memphis, TN, USA) 1%, CaCO3 0.5%, Diaion HP-20 (Mitsubishi Chemical, 
Kanagawa, Japan) 1%, and natural seawater collected in Toyama Bay, Toyama, Japan. The pH 
of the medium was adjusted to 7.0 before sterilization. The inoculated flasks were incubated at 
30°C for 5 days with rotational shaking at 200 rpm. 
Extraction and Isolation. After fermentation, 100 mL of 1-butanol was added to each flask, 
and the flasks were shaken for 1 h. The emulsified mixture was centrifuged at 6000 rpm for 10 
min, and the organic layer was separated from the aqueous layer. The organic layer was 
concentrated in vacuo to afford 5.1 g of crude extract from 2.9 L of production culture. The 
extract was successively partitioned between 60% aqueous MeOH (500 mL) and CH2Cl2 (500 
mL × 3) and the latter between 90% aqueous MeOH (250 mL) and n-hexane (250 mL × 3). 
The 90% aqueous MeOH layer was evaporated to dryness (577 mg) and then fractionated by 
reversed-phase ODS column chromatography with a gradient of MeCN-0.1% HCO2H (2:8, 3:7, 
4:6, 5:5, 6:4, 7:3, and 8:2 v/v). Fraction 5 (6:4) was concentrated in vacuo and the remaining 
aqueous layer was extracted with EtOAc. The organic layer was dried over anhydrous Na2SO4, 
filtered, and concentrated to give 27.5 mg of semi-pure material. Final purification was 
achieved by preparative HPLC (Cosmosil Cholester, Nacalai Tesque Inc., 10 x 250 mm, 4 
mL/min, UV detection at 290 nm) with an isocratic elution of MeCN/0.1% HCO2H (63:37) to 
afford 1 (3.7 mg, tR 14.2 min) and 2 (2.4 mg, tR 15.7 min). 
(6E,8Z)-5-Oxo-6,8-tetradecadienoic acid (1): pale yellow amorphous solid; UV (MeOH) λmax 
(log ε) 277 (4.25) nm; IR (ATR) νmax 3050, 2955, 1708, 1689 cm−1; HR-ESI-TOFMS m/z 
261.1453 [M + Na] + (calcd for C14H22O3Na, 261.1461). 
(6E,8E)-5-Oxo-6,8-tetradecadienoic acid (2): pale yellow amorphous solid; UV (MeOH) λmax 
(log ε) 275 (4.30) nm; IR (ATR) νmax 3389, 2929, 1710, 1659 cm−1; HR-ESI-TOFMS m/z 
261.1458 [M + Na] + (calcd for C14H22O3Na, 261.1461). 
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NMR Spin-System Simulation. In order to determine the multiplicity pattern and the coupling 
constants for the double bond system of 2, spin-system simulations were performed using a 
freeware software, nmrpeak.exe [22]. 
Antimicrobial Assay. Antimicrobial activity was evaluated by the liquid microculture method 
using round-bottomed 96-well microtiter plates against five bacteria, Micrococcus luteus 
ATCC9341, Staphylococcus aureus FDA209P JC-1, Rhizobium radiobacter NBRC14554, 
Escherichia coli NIHJ JC-2, Tenacibaculum maritimum NBRC16015, and two yeasts Candida 
albicans NBRC0197 and Saccharomyces cerevisiae S100 as indication strains. Mueller-Hinton 
Broth (Difco), Sabouraud Dextrose Broth (Difco), and Marine Broth (Difco) were used for 
bacteria, yeasts and Tenacibaculum maritimum NBRC16015, respectively. Compounds 1 and 
2, reference drugs, kanamycin sulfate for bacteria, sulfamethoxazole for R. radiobacter 
NBRC14554 and T. maritimum NBRC16015 and amphotericin B for yeasts, were made in 2-
fold dilution series along the longer side of the plates by sequential transfer of 100 µL aliquots 
between the adjacent wells, to which the same amount of medium was pre-dispensed. To each 
well was added a 100 µL suspension of the indication strains prepared at ~106 cfu/mL from a 
culture at the logarithmic growth phase. The solvent vehicle added to the top rows was set at 
the 0.5% of the final culture volume to avoid the effect on the growth of microbes. The plates 
were incubated at 37°C for 20 h for bacteria, at 24°C for T. maritimum NBRC16015, and at 
32°C for yeasts. The tests were done in triplicate and the absorbance at 650 nm was measured 
using a microplate reader. 
Cytotoxicity Assay. P388 murine leukemia cells were maintained in RPMI-1640 medium 
containing L-glutamine (product no. 186-02155) supplemented with 10% fetal bovine serum 
and 0.1 mg/mL gentamicin sulfate. Compounds 1 and 2 and doxorubicin as a reference were 
serially diluted by a factor of 3.16 (half-logarithmic dilution) in a 96-well round bottom 
microtiter plate. To each well were seeded the cells at a final density of 5×103 cells/well, and 
200 µL cultures thus made were incubated for 96 h at 37°C in an atmosphere of 5% CO2 in air 
with 100% humidity. Viability of the cells was visualized by addition of 50 L of medium 
containing XTT (1 mg/mL) and PMS (40 µg/mL) to each well. After incubating for 4 h at 37°C, 
medium was carefully removed by a suction aspirator, and formazan dye formed by respiratory 
reduction by living cells was quantified by measurement of absorption at 450 nm was read by 
a microplate reader to calculate the rate of cell growth inhibition at each concentration, and the 
results of triplicate experiments were plotted on single-logarithmic charts to deduce IC50 values. 
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PPAR Activation Assay. Measurement of PPARα, -β/, and -γ ligand activity was evaluated 
by a luciferase reporter gene assay system. Briefly, COS-1 cells (5  105 cells) were transiently 
transfected with an expression plasmid containing the ligand-binding domain of human PPARα, 
-/ or -γ fused to the GAL4 DNA-binding domain (pPPARα-GAL4, pPPAR-GAL4, or 
pPPARγ-GAL4, 0.25 µg), a luciferase reporter plasmid 17m2G TATA Luc (p17m2G, 1 µg), 
and the pSEAP-control vector (1 µg) (Clontech, CA, USA) by using the Effectene transfection 
reagent. Transfection was performed in 60-mm culture dishes, according to the manufacturer’s 
instructions. After 16 h, the transfected cells were recovered and seeded into 96-well white 
multi-well plates, the indicated concentrations of the test compounds were added, and the plates 
were cultured for an additional 24 h at 37°C in a 5% CO2 incubator. The luciferase activity and 
secreted alkaline phosphatase SEAP activity were measured in each well by using a Steady-
Glo® luciferase assay (Promega, Madison, WI, USA) and Great ESCAPe SEAP Reporter 
System3 (Clontech), according to the manufacturer’s instructions. The SEAP activity level was 
used to correct the luciferase activity in each well. Each data value is presented as the mean ± 
standard error of three experiments. 
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Figure S1. High resolution ESI-TOF mass spectra of (a) (6E,8Z)-5-oxo-6,8-tetradecadienoic 
acid (1) and (b) (6E,8E)-5-oxo-6,8-tetradecadienoic acid (2) 
(a) 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
  
261.1453 [M+Na]+ 
+MS, 0.2min #10
0.0 
0.5 
1.0 
1.5 
2.0 
x104
Intens.
240 245 250 255 260 265 270 275 280 m/z
261.1458 [M+Na]+ 
+MS, 0.2min #10 
0.0
0.2
0.4
0.6
0.8
1.0
x104
Intens.
250 255 260 265 270 275 280 m/z 
141 
Figure S2. UV spectra of 1 and 2 
(a) (1) (MeOH) 
 
 
 
(b) (2) MeOH 
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Figure S3. IR spectra of 1 and 2.  
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Figure S4. 1H NMR spectrum of 1 (500 MHz, CDCl3) 
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Figure S5. 13C NMR spectrum of 1 (125 MHz, CDCl3) 
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Figure S6. DEPT135 spectrum of 1 (125 MHz, CDCl3) 
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Figure S7. COSY spectrum of 1 (500 MHz, CDCl3) 
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Figure S8. HSQC spectrum of 1 (500 MHz, CDCl3) 
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Figure S9. HMBC spectrum of 1 (500 MHz, CDCl3) 
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Figure S10. 1H NMR spectrum of 2 (500 MHz, CDCl3) 
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Figure S11. 13C NMR spectrum of 2 (125 MHz, CDCl3) 
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Figure S12. DEPT135 spectrum of 2 (125 MHz, CDCl3) 
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Figure S13. COSY spectrum of 2 (500 MHz, CDCl3) 
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Figure S14. HSQC spectrum of 2 (500 MHz, CDCl3) 
 
 
pp
m
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
6.
0
6.
5
7.
0
7.
5
8.
0
pp
m
16
0
14
0
12
0
10
080604020
154 
Figure S15. HMBC spectrum of 2 (500 MHz, CDCl3) 
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CHAPTER 6 
 
Conclusion 
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Stony corals and their associated microorganisms are largely neglected for natural product 
screening program. This study was conducted as our preliminary investigation to evaluate the 
coral-associated bacteria in terms of their ability to produce new bioactive metabolites. For the 
isolation purpose, eighteen aquacultured stony corals were used and 278 bacterial strains were 
isolated. Coral-associated bacteria were isolated by serial dilution and spread plate technique 
methods using Marine Agar and isolated pure strains were preserved at -85oC in 20% glycerol 
in Marine Broth. HPLC-UV chemical screening was employed to find new compounds from 
bacteria associated with corals. Isolated bacterial strains were screened using three types of 
seawater based fermentation media (A3M, A11M and A16) supplemented with HP-20. The 
non-ionic polymeric adsorbent, HP-20 was added to all fermentation media in order to increase 
titres by sequestering metabolites, and preventing degradation or decrease the cytotoxic effects 
of final metabolites. In my screening program of coral-associated bacteria, 85 bacterial strains 
collected from different types of cultured stony corals were used. I selected three strains for 
further study on the basis of their HPLC chromatogram profile and UV spectrum profile.  
In this study, I isolated and determined the structure of four new bioactive compounds 
from three stony coral-associated bacteria. First compound was designated as labrenzbactin (1). 
It is a catecholate-type of siderophore isolated from fermentation broth of Labrenzia sp. C1-1. 
Labrenzia is unexplored genus of marine bacteria and to date including 1 only three bioactive 
compounds were reported from this genus. Labrenzia is obligate marine bacteria and cannot 
grow in culture media without NaCl. According to biosynthetic gene cluster database, 
Labrenzia sp. possess biosynthetic genes for the production of polyketide, non-ribosomal 
peptide, and terpenoid. The structure of 1 was determined by spectroscopic analysis including 
NMR and MS, and absolute configuration was determined by advanced Marfey’s method. 
Compound 1 showed antibacterial activities against plant pathogen Ralstonia solanacearum 
and Micrococcus luteus with MIC values of 25 and 50 µg/mL, respectively. Labrenzbactin 
showed weak cytotoxicity against P388 murine leukemia cells with an IC50 of 13 µM. 
Compound 1 is the first reported compound from stony coral-associated bacteria.  
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Labrenzbactin (1) 
Similarly, HPLC-UV screening of Microbulbifer sp. C4-6 collected from stony coral 
Porites sp. led to discovery of a new unsaturated fatty acid, (2Z,4E)-3-methyl-2,4-decadienoic 
acid (2), with a unique methylation pattern. The structure of 2 was determined by NMR and 
MS data. The biosynthesis of 2 was elucidated by incorporation of 13C isotope labeled 
precursors, [1-13C]acetate and ʟ-[methyl-13C]-methionine. Supplementation of 13C-labeled 
precursors was commenced after 24 h and carried out for four times at 24 h interval. The results 
revealed that origin of carbon backbone from acetate units, whereas methyl group from 
methionine. Compound 2 is biosynthetically unique because the carbon which is derived from 
carbonyl carbon of acetate unit is methylated by methionine via SAM. To the best of our 
knowledge, 2 is the first example of a simple fatty acid in which the carbonyl carbon of an 
acetate unit is methylated with SAM. In addition, compound 2 showed weak inhibition against 
Saccharomyces cerevisiae (MIC 100 µg/mL). Microbulbifer is marine obligate bacteria and 
cannot grow without NaCl. Like Labrenzia, Microbulbifer is also neglected for natural product 
drug discovery program. According to the genome sequence database, biosynthetic genes for 
NRPS and siderophore are present in Microbulbifer species which offer researchers to consider 
this genus for the investigation of natural product screening program. 
 
(2Z,4E)-3-Methyl-2,4-decadienoic acid (2) 
Chemical screening of fermentation broth of Micrococcus sp. C5-9 obtained from stony 
coral Catalaphyllia sp. led to the discovery of two new keto fatty acids, (6E,8Z)- and (6E,8E)-
5-oxo-6,8-tetradecadienoic acids (3 and 4). Strain C5-9 readily grows on seawater-based 
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culture media as well as distilled water-based media, thus I considered this strain as halotolerant 
marine bacteria. Chemical structures of 3 and 4 were determined by spectroscopic analysis. 
Compounds 3 and 4 are unsaturated fatty acids containing ketone group at C5, conjugated with 
two carbon-carbon double bonds. Double bond configuration of C8 in 4 was determined by 
assistance of spin-system simulation studies. As microbial metabolites, compounds 3 and 4 are 
unprecedented, in terms of bearing a 2,4-dienone system. Both 3 and 4 displayed antibacterial 
activities against plant pathogen Rhizobium radiobacter and a fish pathogen Tenacibaculum 
maritimum. In addition, compounds 3 and 4 exhibited agonistic activity against peroxisome 
proliferator-activated receptors (PPARs) with an isoform specificity towards PPARα/γ. 
Previous studies revealed that Micrococcus associated with sponges are potential source for 
new bioactive compounds. Micrococcus species are ubiquitous in distribution and several 
compounds were reported from them. However, there is still chance to get new compounds 
from common bacterial taxa group if we isolated such bacteria from unexplored group of 
organisms such as stony corals. To date, there is no compounds reported from stony coral-
associated Micrococcus except compounds 3 and 4. Keto fatty are relatively rare in nature and 
usually reported from plant and animal sources.  
 
(6E,8Z)- and (6E,8E)-5-Oxo-6,8-tetradecadienoic acids (3 and 4) 
In this study, seawater-based fermentation media were used for the screening as well as 
large scale fermentation of bacteria associated with stony corals. Halophilic marine bacteria 
can thrive at high concentration of salts, which allow them to grow in low-cost seawater-based 
fermentation media instead of valuable fresh water-based fermentation media. In addition, 
contamination of fermentation broth can be reduced by using seawater because non-halophile 
cannot grow in high-salt containing media.  
In summary, my research results demonstrate that screening of new natural products needs 
to be concentrated on unique, extreme, underexplored sources or uncommon microbial species 
or bacterial species isolated from such sources. However, tons of secondary metabolites were 
discovered from common type of bacteria recovered from conventional sources. And there is 
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a high risk of finding already discovered metabolites from common type of bacteria. 
Researchers should consider to work with common bacterial taxa if recovered from unexploited 
sources such as stony coral. The present study substantiated that bacteria isolated from 
unexplored source such as stony corals are a potential source of new bioactive compounds. In 
addition, bacteria from unexploited taxa could be the source of new compounds, but bacteria 
from common taxa collected from unexplored sources still can be a potential source of new 
compounds. Thus, coral-associated bacteria are the promising potential source for the screening 
of new bioactive metabolites. 
Our current knowledge on stony coral-associated bacteria and their metabolites remains 
quite scarce and fragmented as it is limited to a few genus of bacteria, i.e., Labrenzia sp., 
Microbulbifer sp., and Micrococcus sp. Further detailed metabolite analysis of stony coral-
associated bacteria of various genera needs to be carried out in larger range to estimate their 
biosynthetic ability to produce new bioactive metabolites and chemical diversity of the 
structures. In this study, Marine Agar was used as an isolation medium and this medium is very 
nutrient rich so it can prevent the isolation of slow growing bacteria because fast growing 
bacteria grow very fast and cover the medium. To address such problem in the future, we can 
use nutrient deficient media or some selective media to isolate specific group of bacteria such 
as Labrenzia species and Microbulbifer species, which already proved themselves as a poteintal 
source of new bioactive compounds. In addition to selective isolation of targeted bacteria, we 
can also use genetic approaches to assess their biosynethtic gene clusters to know the predicted 
types of molecules that can be produced by bacteria. Combination of selective isolation of 
bacterial strains, and analysis of their biosynthetic gene clusters along with HPLC-UV 
chemical screening can save time, cost and resources and can speed up the screening program. 
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